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ABSTRACT 
 
 
 Conjugated linoleic acid (CLA) reduces inflammation via the inhibition of 
cyclooxygenase II , thus reducing prostaglandin E2 (PGE2) production. Conjugated 
linoleic acid has a suggested osteoclast-suppressive role in bone remodeling and 
osteoarthritis, which are dependent on bone resorptive stimulator PGE2. Bone resorption 
marker, deoxypyridinoline (DPD), and bone formation marker, bone alkaline phosphatase 
(BAP), have been modulated by CLA supplementation in other species. Recent research 
in equine exercise physiology investigated dietary supplementation of polyunsaturated 
fatty acids as a possible prevention and treatment for osteoarthritis, but CLA 
supplementation has putative effects on skeletal function or inflammation in horses has 
not been reported. Our objective was to determine the effects of CLA supplementation on 
PGE2 in synovial fluid, BAP and DPD in serum, stride length and fetlock flexion and 
extension at the walk and trot, and body condition in healthy horses at maintenance. 
 In a crossover study, 12 mares were blocked by breed, age, and body condition 
score (BCS) and separated into 2 treatment groups (n = 6/group). Groups were subjected 
to CLA and corn oil (CO) as an isocaloric control for 6 weeks (wk) separated by a 4-wk 
period during which treatment was withheld. Corn oil or CLA supplement (mixed 
isomers; source contained 55% CLA isomers) were incorporated into maintenance-level 
diets at 0.01% body weight (BW) per d over a six week period. Mares were fed 
individually and were restricted to dry lots to quantify forage intake. Synovial fluid, 
blood, rump fat thickness (RFT), BW and BCS were sampled before (d 0) and after (d42) 
of each feeding period. Walk and trot stride length and fetlock range of motion were 
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assessed on d 0 and d 42 of feeding period 1 only.  Immunoassay kits were used to 
quantify BAP and DPD in serum and PGE2 in synovial fluid. 
 There were no observed differences in BW, RFT or BCS between the CLA and 
CO groups. While plasma CLA concentrations were higher in horses fed CLA compared 
to controls (P < 0.001), synovial fluid PGE2, serum BAP and serum DPD did not differ 
with treatment. Additionally, stride length and fetlock extension were not different at the 
walk or trot between treatments, nor was fetlock flexion at the walk. 
 Despite absorption and incorporation of CLA into plasma, mares did not 
experience treatment effects on biochemical markers of joint inflammation, bone 
metabolism or kinematic performance. Examining the effects of CLA supplementation on 
horses at varying levels of growth, exercise, and progression of osteoarthritis may reveal 
more effects as to its potential benefits in the horse. Rate of dietary CLA incorporation, 
duration of supplementation, and isolated isomer studies may improve our understanding 
of these fatty acids in the equine diet. 
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CHAPTER ONE 
 
INTRODUCTION AND LITERATURE REVIEW 
 
 
Impact of osteoarthritis in the horse industry 
 Lameness is common in athletic horses and is the largest factor in temporary loss 
of use or early retirement of racing horses (Rossdale et al., 1985; McIlwraith, 1996).  
Arthritis is the leading cause of lameness in horses (Todhunter, 1992), resulting in 
shortened competitive careers, accrued veterinary expenses for the owner and overall 
economic loss for the industry. Osteoarthritis (OA) in particular affects athletic horses 
and is typified by changes to the articular cartilage surface and matrix composition 
(McIlwraith, 1996).  Osteoarthritis, synonymous with degenerative joint disease, is a 
disease of progressive and permanent inflammation affecting synovial joints and 
therefore often causes swelling, decreased range of joint motion, joint pain and lameness 
(Trotter and McIlwraith, 1996). Osteoarthritis often occurs as a result of prior training 
injuries to joint structures. While bone tissue has the capacity to repair itself completely 
after a biomechanical insult, synovial and cartilaginous tissues do not, thereby weakening 
the joint and leading to future OA (Pool, 1996). However, McIlwraith and van Sickle 
(1981) demonstrated that early osteoarthritis could be induced in the carpus solely from 
synovitis without any traumatic injury to the joint.  
 As articular cartilage progressively deteriorates, radiographic and 
ultrasonographic changes such as joint space narrowing, subchondral bone sclerosis and 
the presence of osteophytes may also be apparent. Other progressive changes to joint 
structures include thickening of the synovial membrane, fibrosis of the joint capsule and 
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chip fractures (Pool, 1996).  Gross structural joint changes induced by OA are 
accompanied by changes to circulating concentrations of proinflammatory cytokines and 
biomarkers of bone and cartilage turnover.  Proinflammatory cytokines are involved in 
the metabolic control of bone and cartilage tissue turnover.  Precursors and products of 
structural tissue formation and resorption indicate bone and cartilage turnover, and 
changes in concentrations are reportedly correlated with progression of OA (Fuller et al., 
2001).  Studies have reported changes in interleukin (IL)-1, IL-6, tumor necrosis factor 
alpha (TNF-α), and prostaglandin E2 (PGE2) in response to OA (Bertone et al., 2001).  
   As inflammation and tissue degeneration associated with OA progresses, the 
affected animal experiences persistent pain, reduced performance and possible early 
retirement and loss of use.  While there is no “cure” for OA, treatments for OA symptoms 
include rest, exercise and physical therapy programs (Grant, 1996), non-steroidal anti-
inflammatory drug (NSAID) therapy (May and Lees, 1996) and the intra-articular 
administration of corticosteroids and cartilage matrix components (Trotter, 1996).  Some 
more invasive and experimental veterinary techniques seek to reverse the effects of OA 
and restore the structural integrity and usefulness of joint tissues.  These techniques 
include joint resurfacing (McIlwraith and Nixon, 1996), interleukin-1 receptor antagonist 
(IRA) protein therapy (Haupt et al., 2005), IRA gene therapy (Frisbie et al., 2002), and 
extracorporeal shockwave therapy (McCarroll and McClure, 2000). 
 Recently, because of their putative anti-inflammatory effects, the fatty acids (FA) 
docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids have been supplemented to 
horses at maintenance (Hall et al., 2004; Hansen et al., 2004; King et al., 2008;) or  in 
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various levels of exercise (O’Connor et al., 2004; Woodward et al., 2007) and OA 
(Manhart et al., 2009). King and colleagues (2008) described the dose-dependent 
accretion of supplemented EPA and DHA in plasma, and subsequent decrease of 
supplemented FA in plasma after their removal from the diet. It is clear that dietary 
supplemental DHA and EPA are absorbed, incorporated into plasma, and available for 
use in the body; however, limited benefits in reducing OA-associated inflammation have 
been demonstrated in the aforementioned studies.  
 Conjugated linoleic acid (CLA) is the collective group of 18-carbon FA isomers 
with a conjugated, two double bond system. Studies in various in vitro and in vivo animal 
models suggest CLA reduces inflammation by modulating production of 
proinflammatory cytokines TNF-α (Butz et al., 2007), IL-1 and IL-6 (Changhua et al., 
2005; Yang and Cook, 2003) and by inhibiting cyclooxygenase II, yielding reduced 
prostaglandin E2 (PGE2) production (Kelly and Cashman, 2004). Bone remodeling is 
dependent on bone resorptive stimulators IL-6 and PGE2 and has also responded to CLA 
treatment (Kelly and Cashman, 2004; Watkins et al., 2007). Therefore CLA may have 
application as a treatment or preventative for inflammation consistent with osteoarthritis. 
However, neither plasma FA effects nor physiological effects of CLA supplementation in 
horses have been published.  
 Therefore, the goal of this pilot investigation was to describe the effect of dietary 
CLA supplementation in healthy, mature, non-exercised horses on plasma CLA isomer 
and arachidonic acid (AA) concentrations, synovial PGE2, bone remodeling, gait 
kinematics, and body composition. This study will establish a baseline effect of CLA in 
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the equine and provide insight for future study of the effects of CLA in horses 
predisposed to or diagnosed with OA.   
Review of skeletal tissue and joint anatomy and physiology   
Organization and function of skeletal tissue 
 Like other organs in the body, mature skeletal tissue is constantly forming new 
tissue and resorbing weak or old tissue in response to environmental conditions and 
stresses in a process called remodeling (Marlin and Nankervis, 2002). Compact bone 
obtains its strength and function from a highly organized structure of bone matrix 
including cells, collagen (specifically type I collagen), glycosaminoglycans (GAGs) and 
is overlaid with inorganic salts, primarily hydroxyapatite (Frandson et al., 2006).  Bone 
forming cells, or osteoblasts, line the periosteum and endosteum of the long bone and 
synthesize and secrete collagen and GAGs (Marlin and Nankervis, 2002).  As the 
collagenous matrix is mineralized, the osteoblasts become housed in Haversian systems 
and become mature osteocytes which maintain communication with rapidly dividing 
osteoblasts, but do not continue to secrete matrix components (Frandson et al., 2006).  
Large, multinucleated osteoclast cells secrete collagenase, lysosomal enzymes and 
phosphatase, which degrade bone matrix and cause minerals of ossified bone to be 
released into extracellular fluid (Marlin and Nankervis, 2002).  The physiological 
environment and biochemical signals stimulating bone metabolism dictate the rates of 
osteoblastic bone formation and osteoclastic bone resorption to yield net loss, gain or 
maintenance of bone tissue. Parathyroid hormone (PTH), calcitonin, and vitamin D 
regulate mineralization and demineralization of bone (Frandson et al., 2006).  Insulin-like 
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growth factor 1 (IGF-1), collagenases, PGE2, nitric oxide (NO), IL-1, IL-6 and TNF-α 
also function in signaling pathways of bone remodeling (Harada and Rodan, 2003; 
McIlwraith 2005).  Prostaglandin E2 stimulates bone resorption (Raisz, 1995) and 
therefore may be involved in subchondral bone changes associated with osteoarthritis. 
Interleukin-1 and IL-6 are implicated in bone remodeling through up-regulation of COX-
II induced PGE2 production and direct stimulation of osteoclasts (Raisz, 1995). 
Skeletal tissue response to osteoarthritis 
 Horses with osteoarthritis (OA) experience altered bone remodeling compared to 
healthy animals (Frisbie et al., 2008; Fuller et al., 2001; Kawcak et al., 2001). This can be 
a result of inflammatory mediators, which are up-regulated in an OA state, increasing 
bone and cartilage tissue turnover. For example, PGE2 is an eicosanoid found in OA-
affected joints which modulates cartilage turnover (McIlwraith, 1996), and, along with 
IL-6, also stimulates bone resorption (Kelly and Cashman, 2004; Watkins et al., 1997).  
Biochemical products of skeletal formation and resorption are often quantified for use as 
non-invasive indicators of bone remodeling. Fuller and colleagues (2001) examined 
racehorses with lamenesses resulting from confirmed OA. The study correlated synovial 
concentrations of bone specific alkaline phosphatase (BAP), a marker of bone formation,  
in affected versus non-affected joints to the degree of articular cartilage damage as an 
indicator of progression of OA.  Bone alkaline phosphatase was higher in affected joints 
compared to non-affected, contralateral joints. Additionally, synovial fluid BAP 
concentration was positively correlated to the degree of articular cartilage damage. These 
findings indicate bone metabolism is altered in horses affected with OA, and that there is 
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a relationship between articular cartilage changes and subchondral bone changes in OA 
(Fuller et al., 2001).  
 A study was conducted which compared serum and synovial fluid biomarkers 
from exercised horses, utilizing a surgically induced arthritis model (Frisbie et al., 2008). 
Synovial fluid and serum were evaluated in arthritic joints created by an osteochondral 
flap (with the unaffected, contralateral joint used as a control) for type I collagen 
degradation, osteocalcin concentrations, and PGE2 concentrations (not examined in 
serum). All three markers were higher in OA-induced joints compared to contralateral, 
unaffected joints at 70 days of exercise after induction of arthritis (Frisbie et al., 2008).  
Additionally, the synovial marker concentrations were higher in exercised horses with 
OA compared to exercised controls without OA. These results indicate that horses with 
OA experience changes in both collagenous bone matrix and mineralized bone content.  
 Other pro-inflammatory molecules, TNF-α, IL-1, IL-6, and PGE2 are reported to 
positively correlate with active OA and are recommended as predictors of joint disease 
(Bertone et al., 2001). These inflammatory predictors of OA are also mediators in the 
signaling pathways of bone resorption, further confirming the alteration of bone 
metabolism in active OA. Another group found that synovial fluid PGE2 concentrations 
were higher in fetlocks of lame horses versus sound controls (De Grauw et al., 2006). 
Although OA was not the primary focus of the study, the data confirm the increased 
concentration of PGE2 in horses experiencing joint pain and lameness. 
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Bone metabolism biomarkers of interest to the current study 
 Activity of bone cells can be discerned by quantitatively evaluating serum and 
synovial fluid concentrations of anabolic or catabolic products, precursors, and regulators 
of bone remodeling utilizing enzyme immunoassays (EIA).  As bone matrix components 
are produced by osteoblasts or resorbed by osteoclasts, matrix macromolecules and their 
subunits or precursors are released into serum circulation.   
 Bone-specific alkaline phosphatase is a protein located on osteoblasts, and is an 
isoform of alkaline phosphatase that specifically functions in the skeletal system, but not 
the hepatic or intestinal systems (Moss, 1982).  Bone alkaline phosphatase concentrations 
are directly related to the matrix-forming activity of osteoblasts and were shown to 
correlate with concentrations of osteocalcin (Bouman et al., 1995), a protein associated 
with bone formation. Therefore, BAP is considered a direct biomarker of the anabolic 
process of skeletal tissue formation (McIlwraith, 2005) and has been utilized in horses to 
assess bone formation rates.  
 Markers of bone turnover, including BAP, were found to increase in two-year-old 
Thoroughbreds subjected to forced exercise compared to non-exercised controls (Price et 
al., 1995). These results indicate an exercise-induced increase in bone turnover, which is 
supported in other literature (Mathiason-Kochan et al., 2001).  
 Synovial BAP concentrations are highly correlated with osteochondral damage 
(Trumble et al., 2008), a state pre-disposed to OA.  In the study, BAP concentrations 
were evaluated in serum and synovial fluid of racing Thoroughbreds with confirmed 
osteochondral damage (in the carpal, metocarpophalangeal or metatarsophalangeal joints) 
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and compared to normal horses (Trumble et al., 2008).  Bone alkaline phosphatase 
concentrations were found to be lower in serum of horses with osteochondral damage 
compared to normal horses. However, BAP was higher in synovial fluid of damaged 
versus healthy joints. Overall, BAP was higher in synovial fluid from both damaged and 
healthy carpi compared to metacarpophalangeal or metatarsophalangeal joints (Trumble 
et al., 2008). These results indicate that BAP is useful as an indicator of joint damage in a 
pre-arthritic state, making it a useful marker in examining bone turnover with specific 
interest to equine osteoarthritis.  
 Deoxypyridinoline (DPD) and pyridinoline (PYD) are pyridium proteins which 
crosslink subunits of type 1 collagen, giving strength to bone matrix (Seyedin and Rosen, 
1990). As bone matrix is metabolized, the enzyme lysyl oxidase acts to cleave DPD and 
PYD crosslinks from collagen and release the molecules into circulation (Seibel et al., 
1992). Since DPD is highly specific to bone collagen (Seyedin and Rosen, 1990; Seibel et 
al., 1992), the quantification of DPD in serum can help determine the rate of bone 
resorption.  Deoxypyridinoline released from matrix exists in free and bound forms, in 
which a portion of DPD is bound to oligopeptides or large crosslinked structures (Robins, 
1995). The measurement of total DPD can be accomplished after a hydrolysis step to 
release bound DPD.   
  Research in polyunsaturated FA supplementation as a treatment for OA 
 Current methods of treatment for OA focus on management of pain and 
inflammation and are limited inability to reverse damage. New treatments such as joint 
resurfacing, IL-1 receptor antagonist protein therapy and extra-corporeal shockwave 
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therapy, are increasingly invasive and expensive. Recent research in alternative methods 
of treatment has focused on the supplementation of polyunsaturated fatty acids (PUFA) 
because of their putative role in the reduction of inflammation (Ruxton et al., 2004).  
Docosahexaenoic and Eicosapentaenoic Acid Supplementation 
 Two specific PUFA, DHA and EPA have been studied for anti-inflammatory 
effects in horses at maintenance (Hall et al., 2004; Hansen et al., 2002; King et al., 2008), 
or in various levels of exercise (O’Connor et al., 2004; Woodward et al., 2007) or OA 
(Manhart et al., 2009).  Eicosapentaenoic acid and DHA are commonly derived from 
marine organisms for nutritional supplementation to humans and animals (Herold and 
Kinsella, 1986). Docosohexaenoic acid is a 22-carbon FA with 6 double bonds between 
carbons while EPA contains 20 carbons and 5 double bonds.  Both of these PUFA are 
omega-3 FAs, meaning their first double bond from the methyl, or omega, end is between 
the third and fourth carbon atoms from the methyl group.   Docosohexaenoic acid and 
EPA have appeared in circulating plasma in a dose-dependent manner after 
supplementation of DHA- and EPA-enriched sources (Woodward et al., 2007; King et al., 
2008; Manhart et al., 2009). These results indicate that horses absorb dietary PUFA, 
allowing them to be incorporated into tissues and theoretically making them available for 
physiological function.  When EPA and DHA (approximately 46% EPA and 54% DHA) 
were fed at 4 levels (approximately 0, 20, 40 and 81 mg/kg BW per d) for 28 d, all three 
groups receiving the supplement had higher plasma concentrations of EPA and DHA 
compared to controls (King et al., 2008). Eicosapentaenoic acid and DHA were elevated 
in plasma of treated horses by d 3 after initiation of treatment and peaked in 
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concentration by d 7. Nine d after cessation of treatment, EPA and DHA had declined, 
and were not different from controls by 42 d (King et al., 2008).   
 Although most equine studies demonstrate that supplemented PUFA appear in 
plasma, treatment effects on inflammatory markers are conflicting. When mature and 2-
year-old horses exercised 5 d per wk were treated with approximately 3 mg/kg BW EPA 
and 7 mg/kg BW DHA per d for 75 d, there was no difference in concentration of PGE2 
metabolite and TNF-α or lameness scores compared to controls (Woodward et al., 2007). 
Additionally, there was no treatment effect on walk or trot stride length.  Although 
plasma DHA concentration did increase in treated horses, EPA was not elevated in the 
PUFA-fed group compared to controls, indicating EPA may require a higher 
supplementation rate than 3 mg/kg BW to alter plasma FA concentrations (Woodward et 
al., 2007).  The low rate of EPA supplementation may help explain the lack of anti-
inflammatory treatment effect in this study. Additionally, AA was higher in plasma of 
horses consuming the PUFA diet compared with controls, despite there being negligible 
amounts of AA in the PUFA supplement (Woodward et al., 2007). Arachidonic acid is a 
direct precursor in the eicosanoid production pathway, and increased concentration of AA 
may increase inflammatory capacity.  The increase in plasma AA concentrations and 
subsequent increase in availability of AA for eicosanoid production may also lend to the 
lack of anti-inflammatory treatment effect seen in this study.    
 In another study, horses with confirmed arthritis were fed either 19.8 g DHA per d 
and 15 g EPA per d or a control diet for 90 d (Manhart et al., 2009).  Synovial fluid 
concentrations of TNF-α and IL-1 were not different among groups, but synovial fluid 
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white blood cell (WBC) concentration was lower in PUFA-treated horses versus controls.  
Prostaglandin E2 concentration was lower in plasma of PUFA-treated horses compared to 
controls, but weight distribution on the arthritic limb while standing (measured by force 
plates) was not different among treatments (Manhart et al., 2009).  It is interesting to note 
that PUFA-treated horses showed a decrease in plasma PGE2, a systemic inflammatory 
marker, but not of synovial fluid IL-1 or TNF-α, localized inflammatory markers. This 
could be a result of the low supplementation rate of EPA, or it could indicate that EPA 
and DHA cause a systemic effect but do not affect inflammation of the joint.     
Mechanism for anti-inflammatory properties of omega-3 FAs, DHA and EPA 
 Docosahexaenoic acid and EPA are long-chain PUFA which are derived from α-
linoleic acid (18:3, omega-3) as elongase enzymes add carbon atoms and desaturase 
enzymes add double bonds to the FA carbon chain. Eicosapentaenoic acid is one 
precursor for eicosanoid production, which occurs via two pathways: the enzyme 
cyclooxygenase (COX) to produce prostaglandins and thromboxanes, or the enzyme 
lipoxygenase to produce leukotrienes (Calder, 1996).   The eicosanoids produced from 
EPA have a lower biological activity than eicosanoids produced from AA (c20:4, omega-
6). Therefore, the anti-inflammatory properties of EPA and DHA are theoretically 
twofold. First, they competitively inhibit the oxidation of AA by outcompeting AA in 
phospholipid membranes for COX. Secondly, when DHA and EPA enter the COX 
pathway, they yield less biologically inflammatory compounds than if AA were to be 
consumed (Calder, 1996).   
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Conclusions from DHA and EPA supplementation studies in horses 
 Studies agree that dietary supplementation of fat sources containing omega-3 FA, 
specifically DHA and EPA, influence circulating levels of FA when fed at a sufficient 
dose. Supplementation of DHA and EPA causes a decrease in synovial fluid WBC 
concentration (Manhart et al., 2009), indicating anti-inflammatory or immunomodulatory 
effects of the PUFA treatment. In terms of treatment effects on kinematic and kinetic 
performance of the horses, studies reported DHA and EPA supplementation did not 
change stride length, lameness scores, or weight distribution on the OA-affected limb.  In 
conclusion, DHA and EPA supplementation studies show limited benefits in reducing 
inflammation associated with OA or exercise, and may actually increase plasma AA 
concentrations (Woodward et al., 2007; Hall et al., 2004) which could increase capacity 
for inflammation. Therefore further exploration is needed for alternative treatments of 
OA.    
Conjugated linoleic acid is a possible treatment or preventative for OA 
 Conjugated linoleic acid is the term for a group of geometric and positional FA 
isomers, all of which possess two conjugated double bonds along an 18-carbon backbone. 
Individual CLA isomers have been linked with various health benefits in humans and 
animals. Originally discovered in 1985 by Pariza and Hargraves for its anticarcinogenic 
properties, CLA has since been studied for its immune system enhancement, attenuation 
of inflammation, reduction of body fat, and effects on bone remodeling (Hur and Park, 
2007).  The cis-9, trans-11 isomer is the most common dietary isomer and is shown to 
have many roles including anti-carcinogenicity (Battacharya et al., 2006).  The trans-10, 
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cis-12 isomer also has wide biological function, but is known for involvement in anti-
adipogenesis (Park et al., 1999). However, reports are inconsistent and exact roles of each 
isomer cannot be definitively named, as there are likely interactions of CLA isomers yet 
to be elucidated.  The role of CLA supplementation in horses has not been reported. 
Research on effects of CLA treatment on chronic inflammation and bone and cartilage 
metabolism are most relevant to the current study, which investigated the role of 
supplemental CLA in horses.   
CLA and the attenuation of inflammation 
 Several studies suggest CLA attenuates the production of PGE2, an eicosanoid 
and proinflammatory product of cyclooxygenase-II (COX-II), an inducible form of the 
COX enzyme. Kelly and Cashman (2004) found that feeding ovariectomised (OVX) mice 
10 grams of CLA per kg of diet attenuated the OVX-induced increase of PGE2 in ex vivo 
bone cultures.  The authors suggested CLA reduced PGE2 production by outcompeting 
AA in lipid membranes, thereby reducing the amount of AA available for consumption in 
the inflammatory pathway and ultimate COX-II production of PGE2.  Watkins et al. 
(1997) studied the effects of feeding 16 d old chicks anhydrous butter oil (ABO), 
naturally rich in CLA, at 100 g ABO/kg of BW. The chicks consuming ABO produced 
lower levels of PGE2 in ex vivo bone cultures compared to CO-fed control chicks.  
Furthermore, dietary CLA at a dosage rate of 5g/100g diet has been shown to reduce 
TNF-α and arthritis scores, and delay the onset of arthritis in murine models of 
rheumatoid arthritis (Butz et al., 2007). Results from a rheumatoid arthritis model (Butz 
et al., 2007) may be analogous to an osteoarthritis model since COX-II is up-regulated in 
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both types of joint inflammation.  Conjugated linoleic acid is suggested to modulate other 
pro-inflammatory cytokines which are involved in OA-associated inflammation. 
Supplementation of CLA reduced IL-1, IL-6, and TNF-α in pigs injected with 
lipopolysaccharide (LPS) and in in vitro cultured peripheral blood mononuclear cells by 
enhancing the expression of IL-10 and peroxisome prolifator-activated receptor-γ 
(Changhua et al., 2005).  Yang and Cook (2003) found that CLA reduced TNF-α 
production from LPS-stimulated cell cultures. Additionally, CLA supplementation (5 
g/100g) reduced BALB/c mouse plasma TNF-α concentration 2 hr after LPS challenge 
(Yang and Cook, 2003). These reports indicate CLA supplementation may reduce pro-
inflammatory cytokines involved in the chronic inflammation of OA.  
 Prostaglandin E2 is elevated in synovial fluid of horses with arthrogenic lameness, 
but not in sound horses (De Grauw et al., 2006), and is correlated with progression of 
equine OA (Fuller et al., 2001). Conjugated linoleic acid has consistently been shown to 
reduce pro-inflammatory cytokines including PGE2 (Kelly and Cashman, 2004; Watkins 
et al., 1997; Butz et al., 2007, Changhua et al., 2005; Yang and Cook, 2003). Therefore, 
dietary CLA supplementation may decrease PGE2 in horses, resulting in anti-
inflammatory effects particularly in lame or osteoarthritic horses. This may result in 
possible positive effects on joint function and overall athletic performance.   
The role of CLA in energy metabolism and fat storage and utilization 
 As previously mentioned, CLA, specifically the trans-10, cis-12 isomer, has been 
reported to affect body composition (Park et al., 1999).   Dietary CLA supplementation 
(0.5% of total diet) in mice lowered body fat percentage and increased lean muscle mass 
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compared to controls receiving corn oil (Park et al., 1997). In the same study, cultured 
adipocytes treated with CLA showed greater lipoprotein lipase activity with lower 
intracellular triacylglyceride and glycerol content but higher extracellular concentrations 
of free glycerol (in culture medium). The authors inferred CLA initiates an increase in 
lipoprotein lipase activity and overall lipolysis in adipocytes, thereby allowing for body 
fat reduction (Park et al., 1997).   When swine were administered diets containing 0.00, 
0.12, 0.25, 0.50, or 1.00% CLA, desirable carcass performance traits showed responses 
which correlated with CLA supplementation rate (Thiel-Cooper et al., 2001). Average 
daily gain, gain:feed ratio, belly firmness, and bone weight all increased linearly with 
increasing CLA dose. Pigs consuming CLA also had less depth of fat over the loin eye at 
the 10
th
 rib, less intermuscular fat of the loin and less subcutaneous fat at the loin (Thiel-
Cooper et al., 2001).   
 A similar study also reported that CLA affected fat metabolism and body fat 
accumulation (Dugan et al., 1997). Pigs were fed a diet containing 2% CLA or 2% 
sunflower oil as a control.  Pigs consuming CLA were more efficient at converting feed 
to BW gain, had less subcutaneous fat, and had greater lean tissue gain compared to 
controls (Dugan et al., 1997). Data from these studies indicate dietary CLA 
supplementation may have body composition effects in other animals, such as horses, and 
thus will be investigated in the current study. 
The role of CLA in skeletal tissue turnover 
 Conjugated linoleic acid may modulate bone turnover by attenuating production 
of bone-resorptive stimulators, including PGE2 (Butz et al., 2007; Changhua et al., 2000; 
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Kelly and Cashman, 2004; Watkins et al., 1997). Dietary supplementation ABO 
increased tibial bone formation rates in chicks when fed at 100g/kg of diet (Watkins et 
al., 1997) and increased body ash content in mice when fed at 5g/kg of diet (Park et al., 
1997).  In conjunction with CLA treatment decreasing ex vivo bone PGE2 production in 
OVX mice, attenuation of an OVX-induced increase in bone resorption markers PYD and 
DPD (collagen type I crosslinks) in CLA-treated mice was also reported (Kelly and 
Cashman, 2004).   
 Watkins and colleagues (1997) reported higher tibial bone formation rates in mice 
after feeding ABO at 1% of the diet for 16 days, when compared to controls receiving 
soybean oil. Treated mice also exhibited lower ex vivo bone organ culture PGE2 
concentrations and higher insulin-like growth factor-1 (IGF-1) concentrations in bone 
cultures compared to controls. The authors suggested that lower concentrations of PGE2 
were involved in the enhancement of bone formation during modeling and up-regulation 
of IGF-1 to yield more active osteoblastic bone formation (Watkins et al., 1997). 
  Studies of effects of CLA supplementation on human bone metabolism have not 
yielded consistent results.  In a placebo-controlled study, 60 healthy, adult males received 
3 g of a CLA-containing supplement (50:50 mix of cis-9, trans-11 and trans-10, cis-12) 
per d (Doyle et al., 2005).  The subjects were allowed to maintain their own exercise 
regimens. Although men receiving CLA experienced a 3-fold increase in plasma cis-9, 
trans-11isomer, there were no differences between treatment groups for serum 
osteocalcin, BAP, collagen type-1 fragments (marker of degradation), or urinary PYD or 
DPD concentrations (Doyle et al., 2005). Similarly, Krieder and associates (2002) were 
 17 
not able to demonstrate treatment effects of dietary supplementation with 6 g of CLA/d 
on bone mass (measured by dual-energy X-ray absorptiometry) in humans in resistance 
training (Kreider et al., 2002). Effects of CLA supplementation on bone metabolism in 
horses has not been studied and thus is a major focus of the current investigation. 
Specific aims of the current study 
 The current pilot study investigated the effects of dietary CLA in healthy, mature, 
non-exercised horses on plasma FA profiles, synovial PGE2, bone turnover, stride 
kinematics, and body composition. These data will help establish a baseline effect of 
CLA in the equine and provide insight for future study of the potential efficacy of CLA 
supplementation in exercising or OA horses. 
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CHAPTER TWO 
SUPPLEMENTAL DIETARY CONJUGATED LINOLEIC ACID (CLA) INCREASES 
PLASMA CONCENTRATION OF CLA AND DECREASES PLASMA 
CONCENTRATION OF ARACHIDONIC ACID IN HORSES 
 
Introduction  
 Osteoarthritis (OA) affects athletic horses and is a disease of progressive 
inflammation affecting synovial joints, causing swelling, decreased range of joint motion, 
joint pain and lameness (Trotter and McIlwraith, 1996). Recently, because of their 
putative anti-inflammatory effects, docosahexaenoic (DHA) and eicosapentaenoic (EPA) 
acids have been supplemented to horses at maintenance (Hall et al., 2004; Hansen et al., 
2004; King et al., 2008;) during exercise (O’Connor et al., 2004; Woodward et al., 2007) 
and OA (Manhart et al., 2009). King and colleagues (2008) described the dose-dependent 
accretion of supplemental DHA and EPA in plasma, and subsequent decrease of these 
supplemented fatty acids (FA) in plasma after their removal from the diet. However, 
limited benefits in reducing OA-associated inflammation have been demonstrated in the 
aforementioned studies.  
 Conjugated linoleic acid (CLA) is the collective group of 18-carbon FA isomers 
with a conjugated, two double bond system. Studies suggest CLA reduces inflammation 
by modulating production of proinflammatory cytokines tumor necrosis factor-α in mice 
(Butz et al., 2007), interleukin (IL)-1, IL-6 in lipopolysaccharide-challenged pigs 
(Changhua et al., 2005) and mice (Yang and Cook, 2003) and by inhibiting 
cyclooxygenase II, yielding reduced prostaglandin E2 (PGE2) production in 
ovariectomized mice (Kelly and Cashman, 2004). Bone remodeling is dependent on bone 
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resorptive stimulators IL-6 and PGE2, and has demonstrated a response to CLA treatment 
(Kelly and Cashman, 2004; Watkins et al, 2007). Therefore CLA may have application as 
a treatment or preventative for inflammation consistent with OA. However, neither 
plasma FA effects nor physiological effects of CLA supplementation in horses have been 
published. Therefore, the goal of this investigation was to describe the effect of dietary 
CLA supplementation on plasma CLA isomers and arachidonic acid (AA) concentrations 
in horses in preparation for future study on the effects of CLA in models of equine OA or 
increased exercise.   
Materials and Methods 
 This research was approved by the Institutional Animal Care and Use Committee 
of Clemson University (AUP #2009-067).     
Experimental design 
 In a crossover study, light horse mares (n = 12; Quarter Horse, Thoroughbred, and 
Appendix Quarter Horse), 2 to 19 yr in age, and 510 to 645 kg body weight (BW) were 
pair-matched by breed, age and body condition score (BCS) and randomly assigned to 2 
groups, A and B (n = 6/group). The crossover study consisted of two levels of dietary 
treatment fed over two 6-wk feeding periods which were separated by a 4-wk washout 
period in which mares received no treatment. Therefore, mares in group A were fed the 
control treatment (corn oil; CO) during period 1 and CLA during period 2.  Likewise, 
mares in group B were fed CLA during period 1 and CO in feeding period 2. 
 It has been reported that fatty acid supplementation for a duration of 6 wk at a rate 
of 0.002 – 0.008 % BW daily is an adequate supplementation rate and duration of time 
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for the dietary fatty acid to  increase or become detectable in circulating plasma of horses 
(King et al., 2008). The same study showed a decrease in circulating levels of the 
supplemented fatty acid by 9 d after cessation of fatty acid supplementation (King et al., 
2008). Therefore, a feeding duration of 6 wk per feeding period and a total CLA isomer 
inclusion rate of 0.0055% BW per day were selected for the current study.   
Diets 
 All mares were fed isocalorically and isonitrogenously. Diets were designed to 
fulfill maintenance energy requirements of the average maintenance horse according to 
NRC guidelines (NRC, 2007).  The daily diet consisted of coastal bermudagrass hay 
(Cynodon dactylon) fed at a rate of 1.5% BW (as-fed), a commercially available, 
concentrate (Reliance 11, Southern States Cooperative) fed at a rate of 0.3% BW (as-fed), 
and a top-dressed oil supplement (CLA or CO treatment) fed at 0.01% BW (as-fed). The 
CLA source (BASF Corp; Florham Park, NJ) provided 55% CLA (mixture cis-9, trans-
11; trans-10, cis-12; trans-9, trans-11 CLA isomers), yielding a CLA supplementation 
rate of 0.0055% BW (as-fed) . Daily diets were separated into 2 meals, and fed at 0600 
and 1600 daily. There were no significant refusals of diets or treatments. Each mare was 
fed the daily ration in individual stalls and restricted to a drylot (approximately 6 m x 10 
m, or 60 m
2
) which contained 3 to 4 mares each.  Drylots were utilized to prevent 
excessive exercise and unknown dry matter intake. Water was provided ad libitum.   
Management of horses 
 Six days before the first day of the experiment (d -6) mares began a step-up ration 
of oil top-dressed onto a full ration of concentrate, so that 25% of the final amount of 
 21 
daily oil ration was top-dressed on  d -6 and d -5, 50% was top-dressed on d -4 and d -3, 
75% on d -2 and -1, so that mares received the full oil ration (CO or CLA) on d 0 of the 
trial.  This procedure was completed in a step-down manner at the end of each feeding 
period. The incremental introduction and reduction before and after the feeding period 
served two purposes: to prevent major refusals based on novel or unpalatable feed 
ingredients, and to maintain mares on some amount of assigned diet until all 
measurements and biological samples could be taken at the end of the feeding period.  
Biological Sampling 
 Blood was collected via jugular veinipuncture at 0600 h from fasted mares on d 0 
of the trial and weekly thereafter throughout the trial, including the washout period. 
Approximately 20 mL whole blood was collected from each mare into two separate10-
mL evacuated tubes containing K2 EDTA.  Once collected, blood for plasma fatty acid 
analysis was allowed to clot at 4 °C overnight and then centrifuged at 1,300 x g for 10 
min between 4 °C and 10 °C.  Separated plasma was transferred with disposable pipettes 
in duplicate into 30-mL glass culture tubes with Teflon®-lined screw caps and frozen at -
20 °C.  Equal volumes of plasma were transferred from same-horse evacuated tubes to 
create homogeneous plasma duplicates for each mare.  
Chemical Analysis 
 Textured sweet feed, hay, and both oil supplements were analyzed by gas 
chromatography (GC) for concentration of CLA isomers and AA and appear in Table 2.1.  
Textured sweet feed and hay were ground to 0.5 μm before being lyophilized.  
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Table 2.1.  Concentration of selected fatty acids in feedstuffs and supplements fed to 
mares consuming conjugated linoleic acid (CLA) and corn oil (CO; control) treatments 
Fatty Acid 
11% CP 
textured 
sweet feed
a
 
Coastal 
Bermudagrass 
hay
a
 
Corn Oil 
supplement
a
 
CLA 
supplement
a,b
 
cis-9, trans-11 CLA ND ND ND 28.5 
trans-10, cis-12 CLA ND ND ND 28.1 
trans-9, trans-11 CLA ND ND ND 2.5 
arachidonic acid C20:4 ND ND ND ND 
a
ND, not detectable 
b
Fatty acid concentration as a percent of total fatty acid content in the diet component. 
 
 Frozen plasma and diet samples in culture tubes were lyophilized (Lyph-Lock 6, 
Labconco Corp, Kansas City, Missouri), screw caps were reapplied, and freeze-dryed 
samples were maintained at -20 °C. Fatty acids were converted to fatty acid methyl esters 
(FAME) by a previously described two-step methylation procedure (Jenkins, 2010) using 
Tricosylic acid, C23:0, in Toluene as an internal standard (IS) and soybean oil as a 
methylation control.  Briefly, 1.0 mL of IS (2 mg C23:0 per mL of IS) was added to each 
sample duplicate.  Each tube received 2.0 mL sodium methoxide (0.5 M solution in 
methanol), was recapped, vortexed, and incubated in a 50 °C water bath for 10 min, after 
which tubes were removed and allowed to cool for 5 min. Each tube then received 3.0 
mL of 5% methanolic HCl, was recapped, vortexed, and incubated in an 80 °C water bath 
for 10 min. After tubes were removed from the water bath and allowed to cool for 7 min, 
 One mL hexane and 7.5 mL 6% K2CO3 were added to each tube, and tubes were 
recapped and inverted several times to mix. Tubes were centrifuged at 1,000 x g for 5 
min at room temperature to separate layers. Pasteur pipettes were used to transfer at least 
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1.0 mL of the fatty acid-containing hexane layer into 2.0-mL glass autosampler vials, and 
a Teflon®-lined crimp cap was applied. Methylated samples were stored at -20 °C until 
analysis by GC.  Individual FAME were separated by GC on a 100 m x 0.25 mm x 0.2 
μm column (Supelco SP-2560) and detected by a flame ionization detector. Conjugated 
linoleic acid and AA were quantified as a percentage of total fatty acid by comparison to 
the known amount of C23:0 IS.  Before the experiment, plasma fatty acid profiles of 
experimental horses and dietary supplements were inspected for presence of C23:0. 
Neither the CLA supplement nor mare plasma contained C23:0, making it an acceptable 
IS for this study.  
Statistical Analysis 
 All data sets were checked for outliers, normality, constant variance, and if 
applicable, independence of error terms. PROC MIXED with an unstructured covariance 
structure for repeated measures (Littell et al., 2006) was used to test the significance of 
the fixed effects of sequence of treatment, feeding period, treatment, day and treatment 
by day interaction, with individual horse nested within sequence as a random effect. 
These terms were included in the model for the crossover design in order to account for 
variation associated with two separate feeding periods and two opposing sequences of 
treatment administration in order to more accurately assess the treatment effect.  
 Paired t-tests were conducted to determine differences in mean plasma FA 
between treatment groups on any one day, and to determine differences in mean plasma 
FA concentration between days for any one treatment group.  Circulating fatty acid 
concentrations for cis-9, trans-11 CLA; trans-10, cis-12 CLA; trans-9, trans-11 CLA; 
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and AA were analyzed as separate response variables. Concentrations of plasma FA 
which were not detectable were analyzed as values of 0.00. The detection limit was 250 
milivolts. Statistical significance was established with α = 0.050. Statistical analyses were 
conducted using SAS software v. 9.2 (SAS Institute, 2008). 
Results 
 Plasma fatty acid concentrations for all three supplemented CLA isomers and AA 
were elevated (P < 0.001) in supplemented mares compared to controls (Figure 2.1). 
Conjugated linoleic acid isomers were not detectable in plasma of control mares during 
the feeding periods, but all three supplemented CLA isomers increased (P < 0.001) in 
plasma of CLA-treated mares during both feeding periods (Figure 2.1).  
 In addition to these treatment effects, there were fixed effects of day (P < 0.001) 
and treatment by day interaction (P < 0.001), but not sequence or feeding period effects, 
for cis-9, trans-11 CLA in plasma. Plasma fatty acid concentrations of trans-10, cis-12 
CLA exhibited fixed effects of sequence (P = 0.030), feeding period (P = 0.014), day (P < 
0.001), and treatment by day interaction (P < 0.001). There were fixed effects of 
sequence (P = 0.004), feeding period (P < 0.001), day (P < 0.001) and treatment by day 
interaction (P < 0.001) for circulating concentration of trans-9, trans-11 CLA.   
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Figure 2.1. Circulating conjugated linoleic acid (CLA) isomer concentration (percent of 
total plasma fatty acid content) on d 0, 14, 28 and 42 of dietary fatty acid (FA) 
supplementation in mares consuming CLA or corn oil (control) 
 
 
 
P values for crossover design main effects on plasma cis-9, trans-11 CLA: sequence (P = 0.088), period (P 
= 0.062), treatment (P < 0.001), day (P < 0.001) and treatment by day interaction (P < 0.001).  
P values for crossover design main effects on plasma trans-10, cis-12 CLA: sequence (P = 0.030), period 
(P = 0.014), treatment (P< 0.001), day (P < 0.001) and treatment by day interaction (P < 0.001).  
 
P values for crossover design main effects on plasma trans-9, trans-11 CLA: sequence (P = 0.004), period 
(P < 0.001), treatment (P < 0.001), day (P < 0.001) and treatment by day interaction (P < 0.001).  
  
Mean plasma CLA isomer concentrations for the CLA supplemented group are represented with a solid 
line. Plasma CLA isomers were not detectable (ND) in control horses at any time and thus are not 
represented in the figure. Values of 0.0% were used in analyses when plasma concentrations of CLA were 
ND. 
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 Plasma AA concentrations were not different between sequence groups, but did 
exhibit a treatment by day interaction (P = 0.003).  Plasma AA decreased over both 
feeding periods for both CO and CLA supplemented mares (day effect P < 0.001). 
However, mares consuming CLA exhibited lower (P < 0.001) plasma AA concentrations 
compared to controls (Figure 2.2).  The period effect for plasma AA, as analyzed in the 
crossover design (P < 0.001), may be attributed to the difference in d 0 values for AA 
concentrations between periods 1 and 2. A paired t-test indicated d 0 AA concentrations 
in feeding period 2 were lower than in feeding period 1 (P < 0.001), regardless of 
treatment. 
 
 
Figure 2.2. Circulating arachidonic acid (C20:4) concentration on d 0, 14, 28 and 42 of 
dietary fatty acid supplementation in mares consuming conjugated linoleic acid (CLA) or 
corn oil (CO, control). 
Plasma fatty acid concentrations are represented on the Y-axis as a percentage of total circulating 
fatty acid content. P-values for crossover design main effects for plasma C20:4 concentration: 
sequence (P = 0.324), period (P < 0.001), day (P < 0.001), treatment (P < 0.001), and treatment 
by day interaction (P = 0.003).   
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Discussion 
 The current inclusion rate of CLA source (0.55% of the diet as-fed) is similar to 
the CLA source inclusion rate used in a murine model of rheumatoid arthritis (0.5% of 
the diet; Butz et al., 2007). The study reported a reduction in arthritis scores in mice fed 
CLA at 0.5% of the diet per day for 21 days prior to arthritis induction compared to CO-
fed controls. The diet was fed ad-libitum to mice, but weight of diet consumed was not 
noted in the report. Therefore CLA supplementation rate as a percentage of mouse BW 
cannot be compared to the current study. In a second experiment of the same study, CLA 
supplementation at 0.5% of the diet per day (commenced after induction of arthritis) 
delayed the onset of arthritis 4 days compared to CO-fed controls, although peak arthritis 
scores were similar between groups (Butz et al., 2007).  In the current study, the CLA 
source contained 55% CLA (mixed  cis-9, trans-11; trans-10, cis-12; trans-9, trans-11 
CLA isomers) whereas Butz and colleagues (2007) utilized a CLA source that was 
approximately 92% CLA. The resulting inclusion rates of total CLA isomers as a 
percentage of the total diet on an as-fed basis was 0.30% in the current study and 0.46% 
in the study conducted by Butz and colleagues (2007).  The lower dietary CLA inclusion 
rate used in the current study and the species difference in digestive physiology may yield 
anti-inflammatory effects different from those observed in the murine model; therefore 
additional research is needed to establish dose-dependent biological effects of CLA 
supplementation in the horse.   
 The detectability and steep increase of CLA isomers in plasma from d 0 to d 14 in 
feeding period 1, and from d 0 to d 28 in feeding period 2, follows the general trend for 
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fatty acid accretion reported by King and colleagues (2008) when DHA and EPA were 
supplemented at 0, 10, 20 or 40 g/d for 28 d.  In the current study, circulating CLA 
isomer concentrations peaked and plateaued by d 14 in feeding period 1, and by d 28 in 
feeding period 2 (except for trans-9, trans-11 CLA which peaked by d 14). Despite 
similar fatty acid dosage rates, DHA and EPA concentrations consistently peaked at d 7 
(King et al., 2008).  The delay of maximum plasma concentrations of cis-9, trans-12 and 
trans-10, cis-12 isomers in feeding period 2 compared to feeding period 1 could be an 
effect of the crossover design. Although the 4-wk washout period was sufficient for CLA 
to decline in treated horses, there may be lasting effects of fatty acid supplementation on 
lipid metabolism or the ability to competitively incorporate new dietary fatty acids into 
circulation.    
 The finding that supplemented fatty acid can affect circulating plasma fatty acid 
after 7 d of supplementation (King et al., 2008) supports our finding that horses in the 
CLA supplemented group, but not the control group, showed detectable concentrations of 
CLA in circulating plasma at d 0 after a CLA supplement acclimation period beginning d 
-6. Plasma samples were not collected before d -6 of the feeding period as a baseline to 
confirm CLA was not detectable in circulating plasma of mares in the CLA group.  
However, the crossover design allowed all 12 mares to experience both treatments, and 
no mare that showed detectable plasma CLA on d 0 of the CLA-supplementation period 
had detectable plasma CLA at d 0 of their CO-supplementation period, 4 wk after 
cessation of CLA supplementation. Therefore it is unlikely that treatment and control 
groups differed in circulating concentrations of CLA isomers on d  -6 of each feeding 
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period when mares began receiving small amounts of supplemental oil.  Additionally, 
King and colleagues (2008) reported CLA to be non-detectable by GC in all of their 
horses (n=16) across treatments and days.   
 As previously indicated, none of the 6 mares consuming CLA in feeding period 1 
had detectable concentrations of CLA isomers in circulating plasma on d 0 of feeding 
period 2, after the 4-wk washout period.  This finding indicates that four wk is sufficient 
for plasma CLA concentrations to return to pre-supplemental levels after removal of the 
CLA source from the diet, which is supported in n-3 FA supplementation studies in 
horses (Hall et al., 2004; King et al., 2008).   
 Of the isomers detectable in the CLA supplement, cis-9, trans-11 and trans-10, 
cis-12 CLA had concentrations proportional to each other in the supplement and in 
circulation. However, the trans-9, trans-11 isomer was less than one tenth of the 
concentration of either of the cis, trans or trans, cis isomers within the supplement, but 
was 1.5 times greater than the other supplemental isomers in circulating plasma.  
Although we expected CLA isomers to have the same distribution in circulation as in the 
CLA supplement, there are a few possible explanations for this phenomenon. The cecum 
of a horse contains microbes that may have the ability to isomerize linoleic acid (C18:2) 
to produce trans-9, trans-11 CLA as well as other CLA isomers; however, even if these 
microbes exist, the CLAs may not be absorbed by the cecal epithelium. In addition, this 
would require that linoleic acid bypass absorption in the small intestine in order to be 
present in the cecum, which is unlikely.  
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 It is also possible that the trans-, trans- geometric structure of the isomer alters its  
absorption or metabolism within the body.  Most CLA studies are directed toward the cis-
9, trans-11 and trans-10, cis-12 CLA isomers, however some studies have reported the 
inclusion of trans-9, trans-11 CLA and its effects in their research.  Kramer et al. (1998) 
fed a commercial CLA supplement containing cis-, trans- isomers (82%) , trans-, trans- 
isomers (10.1%) and cis-, cis-  isomers (7.4%) to pigs and examined tissue for the 
distribution of CLA isomers. Inner backfat, omental fat, free fatty acids and liver 
triacylcgycerols of pigs fed the CLA supplement all had CLA distributions similar to the 
supplement. Interestingly, CLA distributions in other tissue lipid classes, such as liver 
and heart phospholipids, deviated from the CLA distribution of the supplement (Kramer 
et al., 1998). A group of three  trans-,  trans- isomers (10,12 tt; 9,11 tt; and 8,10 tt) was 
reported to be three times more concentrated (as a percentage of total CLA isomers) in 
liver and heart free fatty acids (FFA) in comparison to the diet (Kramer et al., 1998).  The 
authors suggested trans-, trans- CLA isomers are metabolized more slowly than cis-, 
trans- isomers and therefore accumulate in the FFA form, which supports our finding in 
the current study.   
 Elevation of circulating trans-9, trans-11 isomer above the concentrations of cis-
9, trans-11 and trans-10, cis-12 does not necessarily negate the physiological effects of 
these two isomers in our study. Although reports on the physiologic effects of trans-9, 
trans-11 CLA are few, Park and colleagues (1999) found that the trans-9, trans-11 CLA 
isomer had no effect on lipoprotein lipase activity nor on intracellular triacylglycerol or 
glycerol levels in cultured 3T3-L1 adipocytes. The authors suggested trans-9, trans-11 
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CLA is not the CLA isomer responsible for changing body composition. More research is 
required to investigate other physiological effects of trans-9, trans-11 CLA. Plasma 
concentrations of the cis-, trans- isomers in the current study were higher in treated 
horses and were therefore available to the body for incorporation into tissues and cell 
membranes, regardless of plasma trans-9, trans-11 concentration.   
 The current investigation observed a decrease in plasma AA concentrations in 
mares consuming CLA, which is contrary to n-3 FA supplementations studies (Hall et al., 
2004; Woodward et al., 2007).  When Hall and colleagues (2004) supplemented fish oil 
at 3.0% of the diet (as-fed) for 14 wk, circulating AA concentrations were elevated (P < 
0.001) in horses consuming fish oil by d 7 of supplementation, which persisted 
throughout. Horses fed fish oil had AA concentrations which were 3 to 8 times higher 
than controls throughout supplementation, and the authors attributed this to the 0.7% AA 
concentration in the fish oil supplement whereas AA in the control supplement was not 
detectable (Hall et al., 2004).   In a different study, horses exercised 5 days per week 
were supplemented with approximately 3 mg/kg body weight EPA and 7 mg/kg body 
weight DHA per day for 75 days (Woodward et al., 2007). Plasma DHA, but not EPA, 
increased in treated horses compared to controls. Additionally, AA was higher in plasma 
of horses consuming the n-3 FA diet compared with controls on d 50 and d 75, despite 
there being negligible amounts (0.09 mg/kg BW) of AA in the EPA/DHA supplement 
(Woodward et al., 2007).  The elevation of AA in the two aforementioned studies may 
have confounded the putative anti-inflammatory effects of EPA and DHA 
supplementation. However, since AA was not detectable in any of the diet components in 
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our study, the current CLA and CO supplements are ideal dietary FA sources for the 
study of anti-inflammatory effects of CLA supplementation.   
 Supplementing mares’ diets with CLA decreased plasma AA concentrations, 
which could lead to positive anti-inflammatory effects systemically and locally within 
joints.  Arachidonic acid is a primary precursor for eicosanoid production, which occurs 
via two pathways: the enzyme cyclooxygenase (COX) to produce prostaglandins and 
thromboxanes, or the enzyme lipoxygenase to produce leukotrienes (Calder, 1996). If AA 
is outcompeted in phospholipid membranes by CLA from dietary supplementation, COX 
and lipoxygenase may begin to oxidize other fatty acids, yielding eicosanoids lower in 
biological pro-inflammatory activity (Calder, 1996).  Therefore these data indicate 
supplementation of CLA reduces the availability of AA for oxidation and eicosanoid 
production, and could in theory reduce inflammation or prevent a pro-inflammatory state.   
 Plasma concentrations of trans-10, cis-12 CLA; trans-9, trans-11 CLA; and AA 
were affected by feeding period within the crossover design.  In feeding period 1, CLA 
isomers reached peak concentrations by d 14 and plateaued; however, in feeding period 
2, trans-9, trans-11 CLA was the only isomer to reach its peak concentration by d 14. 
The other isomers (cis-9, trans-11 and trans-10, cis-12) reached peak concentrations by d 
28.  Both of these accretion times are substantiated in literature (King et al., 2008; Hall et 
al., 2004), but the fact that the feeding periods behave differently may indicate that 
although a washout period of 4 wk is long enough for supplemental CLA to clear from 
circulation, effects of fatty acid supplementation may affect overall lipid metabolism and 
metabolism of dietary CLA isomers for a longer duration of time.   
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 An additional difference between feeding periods is apparent in plasma fatty acid 
concentrations at d 0 for all four fatty acids analyzed.  At d 0 of feeding period 2, cis-9, 
trans-11 CLA and trans-10, cis-12 CLA were both detectable in CLA-treated mares 
(which consumed CO in period 1), but were not detectable in mares that consumed CLA 
in feeding period 1.  As previously mentioned, the appearance of CLA in plasma of the 
CLA group is due to the inclusion of small amounts of the CLA supplement for 
acclimation beginning on d -6.  However, we would have expected both feeding periods 
to behave similarly, since they were both subjected to the same duration of diet 
acclimation.  There is a possibility that time of year caused the difference between 
feeding periods. The first feeding period occurred between November 3 and December 
16, 2009, while the second feeding period spanned between January 13 and February 25, 
2010. Average daily temperatures (average of daily high and low temperature) ± SD for 
feeding period 1 and 2 were 50 ± 7 °F and 41 ± 6 °F respectively.  If feeding period 2 
sustained temperatures cold enough to metabolically challenge the mares, they would 
have begun to mobilize fat stores to replace energy lost for heat production, thereby 
altering fat metabolism and possibly profiles of fatty acid in circulation, although this was 
not indicated by BW, BCS, or RFT differences.   
 There was a treatment by day interaction for plasma AA, which is evidenced in 
feeding period 2 when plasma AA for the CLA group was numerically higher on d 0 and 
14 compared to the CO group, but numerically lower than controls on d 28 and 42.   The 
interaction is a result of plasma AA for CLA-treated horses in period 2 decreasing over 
 34 
the whole period, while plasma AA for controls in period 2 decreased from d 0 to d 14, 
but not throughout the remainder. 
  The period effect of plasma AA has two probable causes. First, the difference in 
d 0 values for plasma AA between periods indicates the washout period was insufficient 
to allow plasma AA concentrations to return to pre-supplementation levels after the 
decrease in AA observed in feeding period 1 for mares in both treatment groups. Second, 
plasma AA in feeding period 2 does not show the magnitude of decline observed in 
feeding period 1, although it was still significant.  This again may be attributed to a 
longer lasting effect of FA supplementation which may alter lipid metabolism even after 
clearance of the supplemented FA. If this is the case, supplementation of CLA may 
confer anti-inflammatory properties by reducing availability of AA for eicosanoid 
production even after supplementation ceases.    
Conclusion 
 Dietary supplementation of CLA (mixture cis-9, trans-11; trans-10, cis-12; trans-
9, trans-11 CLA isomers) at 0.0055% BW/d over two 6-wk feeding periods is shown 
here to increase circulating concentrations of each of the supplemented CLA isomers and 
to decrease circulating concentrations of AA.  At the current CLA inclusion rate and 
duration of supplementation, CLA is cleared from circulating plasma by 4 wk post-
supplementation. Although circulating AA concentrations in mares fed CO decreased 
over both feeding periods, mares consuming CLA experienced a greater decrease. 
Therefore CLA supplementation may confer positive, anti-inflammatory effects to the 
horse.  Studies with longer durations of CLA supplementation may help clarify the cause 
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of the feeding period effects observed in the current study.  Additionally, studies utilizing 
various CLA inclusion rates and horse models at varying levels of age, exercise, or OA 
progression will develop our understanding of possible effects of CLA in the reduction or 
prevention of inflammation associated with OA. 
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CHAPTER THREE 
EFFECTS OF SUPPLEMENTAL DIETARY CONJUGATED LINOLEIC ACID ON 
BODY COMPOSITION, BIOCHEMICAL MARKERS OF INFLAMMATION AND 
BONE TURNOVER, AND GAIT KINEMATICS IN MATURE HORSES 
 
Introduction 
 Osteoarthritis (OA) affects athletic horses and is a disease of progressive and 
permanent inflammation affecting synovial joints. Therefore OA often causes swelling, 
decreased range of joint motion, joint pain and lameness (Trotter and McIlwraith, 1996). 
Recently, because of their putative anti-inflammatory effects, Docosahexaenoic (DHA) 
and Eicosapentaenoic (EPA) acids have been fed to horses in various levels of exercise, 
OA and management (Hall et al., 2004; Hansen et al., 2004; King et al., 2008; Manhart et 
al., 2009; O’Connor et al., 2004; Woodward et al., 2007). However, limited benefits in 
reducing OA-associated inflammation have been demonstrated.  
 Conjugated linoleic acid (CLA) is the term for a group of 18-carbon geometric 
and positional fatty acid isomers which possess two double bonds. Individual CLA 
isomers have been linked with anti-carcinogenic properties, immune system 
enhancement, attenuation of inflammation, reduction of body fat, and effects on bone 
remodeling (Hur and Park, 2007). Studies suggest CLA reduces inflammation by 
modulating production of proinflammatory cytokines tumor necrosis factor-α (Butz et al., 
2007), interleukin (IL)-1, IL-6 (Changhua et al., 2005; Yang and Cook, 2003) and by 
inhibiting cyclooxygenase II (COX II), yielding reduced prostaglandin E2 (PGE2) 
production (Kelly and Cashman, 2004). Bone remodeling, which is dependent on bone 
resorptive stimulators IL-6 and PGE2, may also respond to CLA (Kelly and Cashman, 
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2004; Watkins et al, 2007). Therefore CLA may have application as a treatment or 
preventative for inflammation consistent with osteoarthritis.   
 The current pilot study investigated the effects of dietary CLA in healthy, mature, 
non-exercised horses on synovial PGE2, bone turnover, gait kinematics, and body 
composition in effort to establish a baseline effect of CLA in the equine and provide 
insight for future study of the effects of CLA in horses predisposed to or confirmed with 
OA.   
Materials and Methods 
 This research was approved by the Institutional Animal Care and Use Committee 
of Clemson University (AUP #2009-067).     
Experimental design 
 In a crossover study, light horse mares (n = 12; Quarter Horse, Thoroughbred, and 
Appendix Quarter Horse), 2 to 19 yr in age, and 510 to 645 kg body weight (BW) were 
pair-matched by breed, age and body condition score (BCS) and randomly assigned to 2 
groups, A and B (n = 6/group). The crossover study consisted of two levels of dietary 
treatment fed over two 6-wk feeding periods which were separated by a 4-wk washout 
period in which mares received no treatment. Therefore, mares in group A were fed the 
control treatment (corn oil; CO) during period 1 and CLA during period 2.  Likewise, 
mares in group B were fed CLA during period 1 and CO in feeding period 2.   
Diets 
 All mares were fed isocalorically and isonitrogenously. Diets were designed to 
fulfill maintenance energy requirements of the average maintenance horse according to 
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NRC guidelines (NRC, 2007).  The daily diet consisted of coastal bermudagrass hay 
(Cynodon dactylon) fed at a rate of 1.5% BW (as-fed), a commercially available, 
concentrate (Reliance 11, Southern States Cooperative) fed at a rate of 0.3% BW (as-fed), 
and a top-dressed oil supplement (CLA or CO treatment) fed at 0.01% BW (as-fed). The 
CLA source (BASF Corp; Florham Park, NJ) provided 55% CLA (mixture cis-9, trans-
11; trans-10, cis-12; trans-9, trans-11 CLA isomers), yielding a CLA supplementation 
rate of 0.0055% BW (as-fed). Daily diets were separated into 2 meals, and fed at 0600 
and 1600 daily. There were no significant refusals of diets or treatments. Each mare was 
fed the daily ration in individual stalls and restricted to a drylot (approximately 6 m x 10 
m, or 60 m
2
) which contained 3 to 4 mares each.  Drylots were utilized to prevent 
excessive exercise and unknown dry matter intake. Water was provided ad libitum.   
Management of horses 
 Mares were previously kept in a variety of housing schemes, so all mares began 
stalled housing with drylot turnout on d -9 of feeding period 1and 2. This was completed 
to diminish the effects of change in housing management on bone turnover, which has 
been previously documented (Hoekstra et a., 1999).  Six days before the first day of the 
experiment (d -6) mares began a step-up ration of oil top-dressed onto a full ration of 
concentrate, so that 25% of the final amount of daily oil ration was top-dressed on d -6 
and d -5, 50% was top-dressed on d -4 and d -3, 75% on d -2 and -1, so that mares 
received the full oil ration (CO or CLA) on d 0 of the trial.  This procedure was 
completed in a step-down manner at the end of each feeding period. The incremental 
introduction and reduction before and after the feeding period served two purposes: to 
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prevent major refusals based on novel or unpalatable feed ingredients, and to maintain 
mares on some amount of assigned diet until all measurements and biological samples 
could be taken at the end of the feeding period.  
Biological Sampling 
 Blood was collected via jugular veinipuncture at 0600 h from fasted mares on d 0 
of the trial and weekly thereafter throughout the trial, including during the washout 
period. Approximately 20 mL of whole blood was collected into two or three evacuated 
tubes with no additive.  Once collected, blood for serum biochemical marker analyses 
was allowed to clot at 4 °C overnight and then centrifuged at 1,300 x g for 10 minutes 
between 4 °C and 10 °C. Separated serum was transferred with disposable pipettes into 
1.5-mL Eppendorf tubes to create as many multiples as possible (equal volumes were 
transferred from evacuated tubes), frozen at -20 °C and stored until they were used to 
determine concentrations of biochemical markers.   
 Synovial fluid (SF) was collected from the carpus of each mare on d 0, 46, 71, 
and 114.  Every effort was made to collect synovial fluid on d 0 and 42 of each feeding 
period. However, arthrocentesis was delayed until after kinematic videography to prevent 
swelling or pain effects of arthrocentesis from confounding gait kinematic analyses. It 
has been reported that SF collection causes a peak in PGE2 concentrations, and can 
remain elevated for up to 14 d after arthrocentesis (Van den Boom et al., 2005). In the 
current study, SF collection between feeding periods was approximately 4 wk apart, and 
some mares displayed heat and swelling remaining for up to 2 wk after arthrocentesis on 
d 46. To prevent residual increases in PGE2 from confounding analysis of joint 
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inflammation, SF was collected from the right carpus of each mare on d 0 and 46 and 
from the left carpus on d 71 and 114. After administration of intravenous sedative, 
surgical clipping, and disinfection of the carpus, aseptic technique and 20 gauge needles 
were utilized to aspirate joint fluid from either the radiocarpal or intercarpal joint space 
into sterile syringes. Approximately 2.0 – 5.0 mL of SF was collected from each horse at 
each collection.  Synovial fluid was immediately injected into ice cold evacuated tubes 
containing K2 EDTA, and was kept on ice while transferred into ice cold 1.5-mL 
Eppendorf tubes for storage at -20 °C until analysis.  
Body Composition 
 Horses were weighed in a fasting state at 0600 h on a digital livestock scale (A 
and A Scales, LLC) on day 0 and weekly thereafter throughout the trial for weekly 
adjustment of diets. Body condition scores (BCS) of mares were assessed by the same 
trained individual on d 0 and weekly thereafter throughout the trial using procedures 
described by Henneke and colleagues (1983). Rump fat thickness (RFT; cm) was 
determined via transdermal ultrasonography (Aloka 500V, probe model U51 5011U-3.5) 
before and after each feeding period (on d 0, 42, 70 and 112).  The probe was positioned 
on a shaved patch of skin midway between the top of the croup and the tailhead, 5 cm 
lateral from the midline as previously described (Westervelt et al., 1976).  
 Kinematic recording 
 High speed video clips (V5.1 and V2.4 Phantom, VisionResearch, Wayne, New 
Jersey) were captured before and after feeding period 1 only, due to availability of proper 
equipment and technical support, and were processed with corresponding software (Cine 
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Viewer 675, VisionResearch, Wayne, New Jersey). The camera was positioned 
perpendicular to and approximately 25 m from the line of travel and leveled with the 
ground. The shutter speed and f-stop were manipulated to provide the best image given 
the available sunlight, which was the primary light source. Mares were walked and 
trotted in-hand at an active yet normal pace in a straight line on a raked dirt track past the 
view of the camera. Handlers were trained to maintain consistent speed for each 
observation on each horse, and observed speed (Table 3.9) was not different between 
days or treatments, yielding an accurate value for stride length at the walk and trot. Each 
video clip contained at least one complete stride cycle as measured by the initiation of 
stance phase until the initiation of the next stance phase of a marked limb, and 6 videos 
were saved per horse in each gait. Anatomical markers were affixed to three specific 
parts of the right front limb of each horse for precise identification of the position of the 
limb throughout the cycle of movement. Circular labels ¾” in diameter were colored in a 
“bulls-eye” fashion to provide enough contrast to identify the coordinates of the center of 
the marker when the digital videos were viewed with software.  Markers were placed on 
the hair directly over three anatomical landmarks: the ulnar carpal bone, the proximal 
attachment of the distal end of the metacarpus, and on the coronet band above the 
estimated center of rotation of the coffin joint.  These three markers created an 
intersection of two vectors by which to measure fetlock angle and a point on the hoof by 
which to measure stride length.  The landmarks were determined for our study according 
to previous work in equine kinematics (Hodson et al., 2000; Holmstrom et al., 1995).  
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 Stride length (cm) was calculated from the digital videos. For the purposes of this 
study, stride length was defined as the distance between the marker on the coronet band 
at the immediate point in time in which the bottom of the hoof was in full contact with 
the ground but before the limb began to bear body weight (the initiation of the stance 
phase), and the coronet marker at the initiation of the subsequent stance phase of the 
same foot.  The high speed video cameras were able to capture 100,000 frames per 
second, yielding highly accurate identification of separate phases of the stride.  Once the 
two particular frames of interest were identified, the X and Y coordinates of the pixels for 
the marker on the coronet band provided means for quantification of stride length.  
Subtraction of the X-coordinates between the two points on the frames of interest gave 
the number of linear pixels the stride length covered.  A pixel:centimeter ratio was used 
to convert the distance of stride length in pixels to distance in centimeters based on the 
exact depth of field from the camera for each horse’s plane of travel. To obtain the 
conversion factor, each horse was fitted with a calibration marker, a stiff rectangular 
marker on which length was indicated in centimeters with enough contrast for the 
viewing software to identify the number of pixels contained in one centimeter. The 
trigonomic cosine function was utilized to find maximum extension (palmar angle) of the 
fetlock joint after determination of the linear pixel length of the two vectors (cannon and 
pastern) creating the fetlock angle. The trigonomic arctangent function was utilized to 
find maximum fetlock flexion (palmar angle).  On some of the captured videos, there was 
insufficient light to illuminate and identify the coronet anatomical marker as the horse 
flexed the fetlock and protracted the limb underneath the body, yielding missing data 
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points in the fetlock flexion angle (walk and trot) data sets, which is reflected in the 
results (Table 3.5).    
Immunoassay quantification of bone specific alkaline phosphatase (BAP)  
 Bone specific alkaline phosphatase was measured in circulating serum with the 
use of a commercial enzyme immunoassay kit (MicroVue BAP EIA kit, Quidel Corp, 
San Diego, CA) which contained all reagents and supplies necessary to complete the 
assay. Briefly, 125 μL of assay buffer was pipetted into all wells of a 96-well plate which 
contained purified murine monoclonal anti-BAP IgG antibody adsorbed onto stripwells. 
Standards, controls, and samples were pipetted into assay wells (20 μL of the reagent or 
sample into the appropriate well) and the plate was incubated at room temperature for 3 
hours. Standards were plated in triplicate, and samples were plated in duplicate or 
triplicate. After sample incubation, the plate was washed four times with a diluted wash 
buffer. Substrate solution was added at a volume of 150 μL per well and the plate was 
incubated at room temperature for 30 minutes.  Stop solution was added at 100 μL per 
well and the optical density (OD) of each well was read on a Powerwave plate reader 
(BIO-TEK Instruments, Inc., Winooski, Vermont) at an absorbance of 405 nm. The OD 
readings of the known standards were used to fit a quadratic curve of the form y = A + 
Bx + Cx
2
 with KC-4 v3.3 software (BIO-TEK Instruments, Inc., Winooski, Vermont).  
Sample BAP concentrations were extrapolated from the standard curve equation, and 
sample concentrations with OD CV of 5.5% or less were accepted. Samples with CV 
exceeding 5.5% were re-ranalyzed, yielding intraassay variation of 5.5%.  Interassay 
variation was 13.2%. 
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Immunoassay quantification of Deoxypyridinoline (DPD) 
 Deoxypyridinoline was measured in circulating serum with the use of a 
commercial enzyme immunoassay kit (MicroVue Total DPD EIA kit, Quidel Corp, San 
Diego, CA). The assay was completed over two days, with a hydrolysis procedure 
completed on day one to release bound DPD and the EIA completed on hydrolyzed 
samples on day two. Briefly, 100 μL of each serum sample was pipetted into a 
microcentrifuge tube containing 100 μL of supplied acid.  Tubes were subsequently 
vortexed and centrifuged for 5 min at 10,000 x g, and 100 μL of supernatant was 
transferred from each tube to a well in a hydrolysis plate (96-well format).  A silicone 
mat with individual well plugs was placed over the hydrolysis plate to prevent 
evaporation while the plate was heated in an oven at 99 °C for 18 - 20 hr.  During 
heating, the hydrolysis plate was held within an aluminum hydrolysis block.   
 On the second day of the procedure, the hydrolysis block and plate were removed 
from the oven and placed on ice until cold.  Hydrolyzed samples were neutralized by the 
addition of 25 μL of assay buffer followed by 25 μL of provided base (10N NaOH).  
Samples were pipetted up and down a minimum of five times to thoroughly mix.  
Standards and controls were prepared as instructed.  The supplied murine anti-DPD 
antibiody-coated 96-well microtiter plate was prepared by pipetting 50 μL supplied assay 
buffer into each well.  Prepared standards were plated in triplicate (50 μL of standard in 
each appropriate well), while 50 μL of plate controls, hydrolysis controls, and neutralized 
samples were plated in appropriate wells in duplicate.  The loaded plate was incubated 
for 30 min at 2 – 8 °C in the dark.  After sample incubation, 50 μL of room-temperature 
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enzyme conjugate solution (containing bovine DPD conjugated to alkaline phosphatase) 
was added to each well and incubated for 120 minutes at 2 - 8 °C in the dark.  The plate 
was then manually washed a total of three times. Working substrate containing p-
Nitrophenyl phosphate was pipetted into each well (150 μL substrate solution per well), 
and the plate was incubated for 120 minutes at room temperature (20 - 28°C).  After 
incubation, 100 μL of stop solution was added to each well in the same pattern and time 
intervals as the substrate solution, and the OD of the plate was read at 405 nm within 15 
min of the stop solution addition. Optical density readings from the known concentrations 
of standards were used to fit a 4-parameter standard curve with the equation y = (A-D)/(1 
+ (x/C)
B
) + D), where y represented the OD of the standard read at 405 nm, and x 
represented the DPD concentration (nmol/L).  Optical densities of samples with a CV 
exceeding 9.0% were re-analyzed, yielding an intraassay variation of 9.0%. Interassay 
variation was 10.01%.  Sample concentration of total DPD (tDPD; nmol/L) was 
extrapolated from the standard curving with KC-4 software. 
 Immunoassay quantification of prostaglandin E2 
 Prostaglandin E2 was quantified in SF with the use of a commercial competitive 
immunoassay kit (PGE2 High Sensitivity kit, Assay Designs, Ann Arbor, Michigan) after 
the extraction of PGE2 from SF.  To extract PGE2 from SF, 0.5 – 1.5 mL SF was acidified 
by addition of 2M HCL to a pH of 3.5 and allowed to sit for 15 min before centrifuging 
for five min at 10,000 x g to remove any precipitate.  Reverse phase extraction columns 
(200 mg C18, Restek Corp, Bellefonte, Pennsylvania) were prepared by washing with 10 
mL of ethanol followed by 10 mL of deionized water. After column preparation, 0.5 mL 
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of acidified sample was applied to the column, and positive pressure was applied to 
achieve a flow rate of approximately 0.5 mL/min.  The column was washed with 10 mL 
of deionized water, followed by 10 mL of 15% ethanol, and finally 10 mL hexane. Next, 
samples were eluted from the column by addition of 10 mL of ethyl acetate, which was 
collected into a 15-mL polypropylene conical tube.  Eluted samples in ethyl acetate were 
stored at -20 °C until assay completion, at which point samples were evaporated under 
nitrogen gas and 1.0 mL of supplied assay buffer was added to dried samples. Samples 
were vortexed and allowed to rest for five min. The vortex and rest step was completed 
twice more. All kit reagents and standards were prepared according to instructions, and 
samples were plated in duplicate or triplicate.  Briefly, 100 μL of standards were pipetted 
in triplicate into wells of the 96-well microtiter plate which was coated with goat anti-
mouse IgG. Samples (100 μL per well) were pipetted into appropriate wells. 
Prostaglandin E2 conjugate solution (containing PGE2 conjugated to alkaline 
phosphatase) was pipetted into each well (50 μL conjugate solution per well), and 50 μL 
of monoclonal PGE2 antibody was pipetted into each well. The plate was sealed and 
incubated at 4 °C for 18 – 24 hours. After incubation, the plates were washed three times. 
Substrate solution containing p-nitrophenyl phosphate was added (200 μL per well) to 
every well, and the plate was sealed and allowed to incubate for 1 hr at room temperature. 
Next, 50 μL of stop solution was added to each well, and the OD of each well was 
immediately read at an absorbance of 405 nm. Optical density readings from the known 
concentrations of standards were used to fit a 4-parameter curve with the equation y = 
(A-D)/(1 + (x/C)
B
) + D), where y represented the OD of the standard read at 405 nm, and 
 47 
x represented the PGE2 concentration (pg/mL).  Samples with an OD CV exceeding 6.2% 
were re-analyzed. The intrassay variation was 6.5% and the interassay variation was 
8.3%.  Sample concentrations of PGE2 (pg/mL) were extrapolated from the standard 
curving with KC-4 software. Sample concentrations were adjusted for the dilution during 
reconstitution after the extraction step.   
Statistical Analyses 
 All data sets were checked for outliers, normality, constant variance, and if 
applicable, independence of error terms. An ANOVA was conducted to compare 
response between the treatment and control group means. A term describing change in 
response on a parameter from pre-trial to post-trial was used as the response variable in 
the analysis. The response variable was generated by subtracting the d 0 treatment mean 
from the d 42 treatment mean (d 42 – d 0) over both feeding periods. The model for the 
crossover analysis also included terms for feeding period, sequence of treatment 
administration, and individual mare as a random effect. These terms were included in the 
model for the crossover design in order to account for variation associated with two 
separate feeding periods and two opposing sequences of treatment administration in order 
to more accurately assess the treatment effect. T-tests were conducted to identify 
differences between  treatments or feeding periods within a d (d 0 or d 42). 
 Since kinematic data were only collected during feeding period 1, treatment group 
response means for d 0 and 42 were subject to t-tests to test for significant differences. A 
t-test was completed on stride duration ([stride length] / [speed]) for the walk and trot to 
test for treatment effects. Stride length was divided by speed to account for any error due 
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to speed differences between observations on d 0 and d 42. A t-test was completed on 
maximum fetlock extension angle and maximum fetlock flexion angle at both gaits for 
data collected in feeding period one. Statistical significance was established with α = 
0.050. Statistical analyses were conducted using SAS software v. 9.2 (SAS Institute, 
2008). 
Results 
Body composition 
 Conjugated linoleic acid treatment did not have a treatment effect on BW, BCS or 
RFT.  Table 3.1 contains the mean BW (kg),  mean BCS, and RFT (cm)  ± SD for mares 
consuming CLA or CO at d 0 and d 42 of feeding, and the LS mean ± SE for difference 
in response (d 42 – d 0) over the feeding period, the response variable for the analysis. 
Body weight (kg) was not affected by treatment (P = 0.560), treatment sequence (P = 
0.404) or feeding period (P = 0.345).  Body condition score was not affected by treatment 
(P = 0.709), treatment sequence (P = 0.221) or feeding period (P = 0.277).  Change in 
RFT was numerically higher in mares consuming CLA compared to controls; however, 
the difference was marginally insignificant (P = 0.075). Rump fat thickness was not 
affected by sequence of treatment administration (P = 0.641) or feeding period (P = 
1.000).  
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Table 3.1.  Mean body weight (BW; kg), body condition score (BCS), and rump fat 
thickness (RFT; cm) ± SD and LS mean difference (diff) in response (d 42 – d 0) ± SE 
for mares receiving supplemental dietary conjugated linoleic acid (CLA) and corn oil 
(CO; control), regardless of feeding period 
  Treatment 
Item Time CLA (n=12) CO (n=12) 
T-test  
P-value 
(within day) 
ANOVA  
P-value 
BW 
(kg) 
d 0 558 ± 41 556 ± 38 0.1886  
d 42 557 ± 42 556 ± 41 0.6401  
Diff (d 42 – d 0) -0.88 ± 1.76 0.62 ± 1.76  0.5602 
BCS 
d 0 5.75 ± 1.03 5.71 ± 0.99 0.8380  
d 42 5.79 ± 1.08 5.83 ± 1.23 0.6742  
Diff (d 42 – d 0) 0.04 ± 0.15 0.13 ± 0.15  0.7094 
RFT 
(cm) 
d 0 1.15 ± 0.58 1.25 ± 0.63 0.1292  
d 42 1.20 ± 0.63 1.23 ± 0.69 0.7467  
Diff (d 42 – d 0) 0.06 ± 0.04 -0.03 ± 0.04  0.0753 
 
Bone metabolism and inflammatory biomarkers 
 Concentrations of serum bone metabolism marker DPD (nmol/L) was not 
different between treatments (P = 0.752).  Difference in DPD concentration was not 
different between feeding periods (P = 0.625) or between treatment sequence groups (P = 
0.534). Table 3.2 contains the mean serum DPD concentration (nmol/L), serum BAP 
(U/L), and synovial PGE2 (pg/mL) ± SD for mares consuming CLA or CO at d 0 and d 
42 of feeding, and the LS mean ± SE for difference in response (d 42 – d0).  
 Change in BAP concentrations (d 42 – d 0) for horses consuming CO were not 
different from BAP change for horses consuming CLA (P = 0.972).  There was no effect 
of treatment sequence on change in BAP concentration (P = 0.673).  The BAP change for 
horses in feeding period 1 was not different than BAP change for horses in feeding period 
2 (P= 0.781).   
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 Table 3.3 contains the mean serum BAP concentrations ± SD, and the LS mean 
difference in response (d 42 – d 0) ± SE for mares in feeding periods 1 and 2.  Bone 
alkaline phosphatase concentration decreased during feeding period 1 (P = 0.004) and 
feeding period 2 (P < 0.001) when data from both treatments were considered (Table 
3.3).  Mean BAP was lower on d 0 of feeding period 2 compared to feeding period 1 (P = 
0.006) when data from both treatments were considered.  Mean BAP concentrations on d 
42 of feeding period 1 and d 0 of feeding period 2 (after a 4-wk washout period) were not 
different (P = 0.189). 
 Change in PGE2 concentration (pg/mL; d 42 – d 0) was not different between 
treatments (P = 0.174) or treatment sequence groups (P = 0.880; Table 3.2). There was, 
however, an effect of feeding period on PGE2 change (P < 0.001; Table 3.3).  Mean PGE2 
concentration on d 0 of both feeding periods was numerically higher compared to day 42, 
regardless of treatment. However, the difference was marginally insignificant (P = 
0.059). There was horse-to-horse variation (P < 0.001) for synovial PGE2. This is 
demonstrated in the numerically dissimilar SD between d 0 and d 42 for both treatments 
(Table 3.2) and both feeding periods (Table 3.3), which were caused by one particular 
horse. The mare was not a statistical outlier, and her effect on the variability of the 
parameter was similar on both feeding periods and both treatments; therefore, the mare’s 
observations were not removed from analysis.    
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Table 3.2.  Mean serum deoxypyridinoline (DPD; nmol/L), bone alkaline phosphatase 
(BAP; U/L) and synovial prostaglandin E2 (PGE2; pg/mL) ± SD and LS mean difference 
(diff) in response (d 42 – d 0) ± SE for mares receiving supplemental dietary conjugated 
linoleic acid (CLA) and corn oil (CO; control), regardless of feeding period 
  Treatment 
Item Time CLA (n=12) CO (n=12) 
T-test  
P-value 
(within day) 
ANOVA 
P-value 
Serum 
DPD 
(nmol/L) 
d 0 4.99 ± 0.99 5.11 ± 1.23 0.944  
d 42 5.41 ± 1.18 5.55 ± 1.01 0.619  
Diff (d 42 – d 0) 0.15 ± 0.48 0.38 ± 0.48  0.756 
Serum 
BAP 
(U/L) 
d 0 34.97 ± 9.82 35.31 ± 12.37 0.904  
d 42 23.91 ± 11.22 24.38 ± 19.06 0.897  
Diff (d 42 – d 0) -11.06 ± 2.58 -10.93 ± 2.58  0.973 
Synovial 
PGE2 
(pg/mL) 
d 0 82.72 ± 50.29 79.98 ± 48.28
*
 0.442  
d 42 58.45 ± 19.40 63.45 ± 19.34 0.525  
Diff (d 42 – d 0) -24.27 ± 4.75 -13.69 ± 5.20*  0.373 
*missing observation, n=11.   
 
 
 
 
 
Table 3.3.  Mean serum bone alkaline phosphatase (BAP; U/L) and synovial 
prostaglandin E2 (PGE2; pg/mL) ± SD and LS mean difference (diff) in response (d 42 – 
d 0) ± SE for mares in feeding periods 1 and 2, regardless of treatment 
  Feeding Period 
Item Time 1 (n=12) 2 (n=12) 
T-test 
P-value 
(within day) 
ANOVA 
P-value 
Serum 
BAP 
(U/L) 
d 0 38.33 ± 9.98
a
 31.95 ± 11.31
b
 0.006  
d 42 27.86 ± 18.05
a
 20.44 ± 11.54
b
 0.017  
Diff (d 42 – d 0) -10. 47 ± 2.58 -11.51 ± 2.58  0.781 
Synovial 
PGE2 
(pg/mL) 
d 0 72.69 ± 51.68 90.92 ± 44.59
*
 0.068  
d 42 70.91 ± 17.65
a
 50.98 ± 15.37
b
 0.002  
Diff (d 42 – d 0) -1.78 ± 4.75a -36.19 ±5.20b*  < 0.001 
Within a row, different superscripts indicate differences between feeding period means.  
*missing observation, n=11.   
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Gait Kinematics 
 Change in stride length (cm; d 42 – d 0) was not different between treatment 
groups at the walk (P = 0.538) or trot (P = 0.631). A t-test was completed on stride 
duration ([stride length; cm] /[speed; cm/sec]) for the walk and trot to test for treatment 
effects while accounting for any error due to speed differences between observations. 
Mean stride duration was not different between treatments at the trot (P = 0.708) or the 
walk (P = 0.984). Stride length, speed, and stride duration means for d 0, d 42, and 
difference in kinematic response (d 42 – d 0) appear in Table 3.4.  
 
Table 3.4.  Mean stride length (cm), speed (cm/sec) and stride duration (sec) ± SD at the 
walk and trot on d 0 and d 42 and difference (diff)  in response (d 42 – d 0) ± SD for 
mares receiving supplemental conjugated linoleic acid (CLA) or corn oil (CO; control) 
*missing observation (n=5) 
 
 
Item 
Treatment 
(n = 6 per 
treatment) d 0 d 42 
Diff  
(d 42 – d 0) 
P-
value 
Walk stride 
length, cm 
CO  148 ± 13 155 ± 12 7.22 ± 9.22 
0.538 
CLA  152 ± 10 157 ± 5 4.40 ± 5.69 
Walk speed, 
cm/sec 
CO 120 ± 14 130 ± 11 8.78 ± 15.97 
0.589 
CLA 124 ± 15 132 ± 11 7.03 ± 7.29 
Walk stride 
duration, sec 
CO  1.23 ± 0.09 1.19 ± 0.09 -0.04 ± 0.10 
0.984 
CLA  1.23 ± 0.11 1.19 ± 0.07 -0.04 ± 0.10 
Trot stride 
length, cm 
CO  183 ± 15 180 ± 18 -2.67 ± 7.99 
0.631 
CLA 191 ± 15* 183 ± 10 -8.87 ± 7.99* 
Trot speed, 
cm/sec 
CO 267 ± 36 254 ± 16 -12.90 ± 42.50 
0.884 
CLA  270 ± 29* 252 ± 14 -17.27 ± 19.33* 
Trot 
duration, sec 
CO 0.69 ± 0.05 0.71 ± 0.05 0.02 ± 0.03 
0.708 
CLA 0.71 ± 0.04* 0.72 ± 0.04 0.01 ± 0.03* 
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 Paired t-tests indicated that mean palmar fetlock angle at maximum extension was 
not different between treatments at the walk (P = 0.729) or the trot (P = 0.220; Table 3.5). 
There was no treatment effect of CLA supplementation on mean palmar fetlock angle at 
maximum flexion at the walk (P = 0.717; Table 3.5).  A t-test for treatment effect was not 
completed on data for maximum fetlock flexion angle at the trot, as the control group 
contained only one observation. 
 
 
Table 3.5.  Mean maximum palmar fetlock extension angle (°) and maximum palmar 
fetlock flexion angle ± SD at the walk and trot on d 0 and d 42 and difference (diff) in 
response (d 42 – d 0) ± SD for mares receiving supplemental conjugated linoleic acid 
(CLA) or corn oil (CO; control) 
*Missing observation (n=5) 
a
There was no treatment difference for change in fetlock extension at the walk (P = 0.729). 
b
There was no treatment difference for change in fetlock flexion at the walk (P = 0.717). 
c
There was no treatment difference for change in fetlock extension at the trot (P = 0.220). 
d
Analyses were not completed on fetlock extension angle at the trot for lack of replicates in the 
control group. 
 
 
 
Item 
Treatment  
(n = 6 per 
treatment) d 0 d 42 
Diff  
(d 42 – d 0) 
Walk fetlock 
extension, ° 
CO  226.29 ± 4.86 229.36 ± 4.21 3.07 ± 2.62
a
 
CLA 227.68 ± 5.81 229.77 ± 3.48* 2.33 ± 4.19*
a
 
Walk fetlock 
flexion, ° 
CO  152.09 ± 2.00  160.95 ± 5.62  8.87 ± 13.24
b
  
CLA  152.86 ± 10.94 158.46 ± 5.62 5.78 ± 7.35
b
 
Trot fetlock 
extension, ° 
CO 236.87 ± 5.53 242.19 ± 4.81  5.33 ± 4.32
c
 
CLA  240.49 ± 4.98* 242.21 ± 3.31 1.92 ± 4.19*
c
 
Trot fetlock 
flexion
d
, ° 
CO (n=1) 153.5 ±  145.5 ±  -8.00 ± 
CLA (n=3) 135.13 ± 9.35  146.46 ± 8.99  12.07 ± 2.54 
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Discussion 
Body Composition 
 Results of this study indicate that CLA supplementation does not have a effect on 
body composition (BW, BCS, or RFT) at the stated plane of nutrition and requirements, 
CLA inclusion rate, and supplementation length. The specific CLA isomer known for 
anti-adipogenic properties, trans-10 cis-12, was present in the CLA supplement and 
showed a treatment-induced increase in circulating plasma (data not shown). Thiel-
Cooper et al. (2001) demonstrated that performance carcass traits in swine responded to 
CLA supplementation in growing-finishing hogs. The mares in the current study 
however, were in a physiological state of maintenance, not of skeletal or muscle 
development as with growing-finishing pigs, which could contribute to the difference in 
results between this study and the current study. Additionally, the supplementation rate of 
CLA in hogs was higher (up to 1.0% of the total diet; Thiel-Cooper et al., 2001) 
compared to the current experimental diet which contained 0.55% CLA supplement 
(CLA isomers were 0.30% of diet) as-fed. Although CLA supplementation did not affect 
body composition of mares at maintenance energy requirements, it may still have effects 
in horses with various caloric demands or intakes, such as growing, exercised or obese 
horses.  
Bone metabolism and inflammatory biomarkers 
 While there were no treatment differences for BAP change (post – pre) in our 
study, there was a decrease in BAP concentration from pre-supplementation to post-
supplementation, indicating a decrease in osteoblastic activity during each of the feeding 
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periods. We attribute this effect to a change in housing (and therefore exercise and bone 
loading), as most of the mares in the experiment were previously housed on pasture and 
were confined to stalls and small lots during the feeding periods. It has previously been 
reported that confinement housing decreases markers of bone formation (Maenpaa et al., 
1988) and increases markers of bone resorption (Hoekstra et al., 1999).  
 In an effort to reduce the effect of housing-induced bone resorption, we began 
stalled housing at d -9 to allow the mares time to acclimate to new housing management 
and turned mares out into 60 m
2
 dry lots after meals. The results of the current study 
indicate 9 d is insufficient to allow for complete acclimation to a change from pasture-
based management to stalled housing for healthy, mature, unexercised mares. A sufficient 
acclimation period between 28 and 56 d is supported by data from Hoekstra and 
colleagues (1999) in yearling horses that were moved from pasture to stalls. The authors 
reported elevated urinary DPD in stalled yearlings versus contemporaries housed on 
pasture at 14 and 28 d, but not 56 d of confinement (Hoekstra et al., 1999). Maenpaa et 
al. (1988) reported a reduction of osteocalcin (a marker of bone formation) when foals 
were transferred from pasture to stalled housing.  
 In the current study, the 4-wk washout period was designed to allow the mares to 
return to a physiological state similar to d 0 of the trial, and thus, the mares were returned 
to pasture. The difference of serum BAP concentration on d 0 of feeding period 1 and 2 
indicates that the washout period was insufficient to allow bone to return to a pre-trial 
state. However, since treatment and control animals experienced the same housing, and 
the term for feeding period was included in the statistical model, the statistical results for 
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other terms in the analysis of BAP concentration are reliable. Confinement-induced 
suppression of osteoblasts may act as a stronger physiological stimulus than CLA 
supplementation in non-exercising mares and mares without joint disease, thereby 
possibly masking effects of dietary CLA on BAP concentrations in our study. Housing-
related changes in bone metabolism could be avoided by utilizing experimental animals 
that have previously been maintained on the housing protocol used in the study, or by 
designing a sufficient housing acclimation period to allow bone marker concentrations to 
stabilize before experimental data is collected. 
 Although BAP, the selected marker of bone formation, decreased across both 
feeding periods regardless of treatment, DPD, the indicator of bone resorption, did not. 
Analysis of serum DPD in this study did not reveal an increase of bone resorption during 
confinement as reported by Hoekstra et al. (1999), which could be attributed to the age 
difference in experimental units used in the studies. Rate of dietary CLA supplementation 
in this study was adequate to alter plasma CLA isomer concentrations in treated mares 
(data not shown) and was therefore theoretically physiologically available to alter bone 
metabolism; however, studies with longer CLA supplementation periods and higher CLA 
inclusion rates may assist in deciphering its effects on bone remodeling.      
 Dietary CLA treatment did not affect PGE2 concentration in carpal synovial fluid; 
however, there was a feeding period effect on PGE2 concentration, with feeding period 2 
having a greater decrease in concentration (d 42 – d 0) compared to the PGE2 decrease in 
feeding period 1.  This could indicate an effect of the washout period on inflammation in 
synovial fluid possibly from bouts of high-speed and high-intensity running when mares 
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were initially let out to pasture for the washout period. Although mares were not 
observed 4 wk before d 0 of the experiment, it is unlikely they exercised to the same 
intensity as the first few days of the washout period while housed on pasture before the 
study.  Since the variation associated with feeding period was incorporated into the 
statistical model, the feeding period effect does not confound our ability to detect a 
treatment effect. Thus, these data indicate that PGE2 in the carpi of non-exercised mares 
without clinical signs of OA is not affected by CLA supplementation at the current 
inclusion rate and duration of CLA supplementation. Additional studies utilizing pro-
inflammatory stressors such as exercise or arthritis induction would aid in developing our 
understanding of the effect of CLA on joint inflammation.   
Gait Kinematics 
 Conjugated linoleic acid supplementation in the current experiment did not impact 
stride length, fetlock extension, or fetlock flexion at the walk or trot. We are particularly 
interested in the action of CLA on inflammation in the joint via the COX-II enzymatic 
pathway and PGE2 production, and resulting joint pain leading to alterations in gait and 
range of motion of joints. Since carpal synovial PGE2 concentrations did not decrease in 
feeding period 1, it follows that stride length would not change from d 0 to d 42. 
Although we did not directly measure inflammation locally in the fetlock, we assume the 
joint structures behave in a similar manner to CLA as the carpus. The lack of treatment 
effect on fetlock extension angle may indicate that CLA treatment did not decrease PGE2 
or other markers of inflammation within the fetlock joint, similar to the effect observed in 
the knee. Unfortunately we were unable to obtain kinematic data for feeding period 2, 
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which would have been worthy to note, given the period effect (crossover design 
analysis) and decrease (paired t-test) in synovial PGE2 concentrations  which occurred 
during feeding period 2, regardless of treatment. It may also be necessary to increase the 
rate of CLA supplementation to observe effects in horses without clinical osteoarthritis or 
lameness. The findings of this study do not necessarily indicate that CLA 
supplementation has absolutely no effect on stride length or other kinematic parameters 
of horses. Further CLA supplementation studies should be completed with higher or 
various CLA inclusion rates and with horses in exercise programs or with confirmed or 
induced joint disease. 
Conclusion 
 No treatment effects were observed for parameters associated with body 
composition, bone metabolism, joint inflammation or gait kinematics, indicating CLA 
does not affect these parameters in healthy, mature, non-exercised horses after six weeks 
of dietary supplementation at 0.0055% BW CLA isomer inclusion rate. Serum bone 
formation marker BAP displayed a decrease over time. Supplementation of CLA did not 
affect PGE2, a biomarker of localized joint inflammation, which is a factor that 
predisposes horses to OA. However, further studies comparing the effects of CLA on 
joint inflammation in exercised versus non-exercised or OA-induced versus non-OA 
horses may reveal different results.   
 The current pilot study was intended to establish an understanding of the baseline 
effects of CLA on non-growing, non-exercising, non-arthritic horses, giving insight for 
development of future studies to test the effectiveness of CLA as a treatment or 
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preventative of OA. The current study indicates CLA does not affect horses used in the 
current study; therefore, further studies should investigate the effects of CLA 
supplementation in vivo with a growth, exercise or induced arthritis experimental model, 
or investigate the effects of CLA on targeted tissues by utilizing ex vivo bone, synovial, 
or cartilage explants in culture.   
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CHAPTER FOUR 
SUMMARY 
 The results of this study indicate that dietary supplementation of CLA to horses at 
0.0055% BW for 6 wk does alter plasma FA concentrations of CLA isomers and AA, but 
not body fat, markers of bone turnover, synovial PGE2 concentrations, walk or trot stride 
length, or fetlock extension or flexion. Horses consuming the CLA treatment showed 
detectable plasma concentrations of CLA by d 14 of supplementation, indicating effective 
digestion and absorption of the supplemented CLA isomers. In contrast, CLA was not 
detectable in plasma of control mares at any point during the study. As supported by 
other FA supplementation studies in horses, the supplemented CLA isomers cleared from 
plasma by 4 wk post-supplementation. Despite this, some of the CLA isomers showed 
differences between feeding periods and treatment sequence groups, revealing potential 
effects of treatment beyond the 4-wk washout required for clearance of the supplemented 
isomers.   
 Dietary CLA supplementation caused a reduction in plasma AA concentrations 
compared to controls. A decrease in circulating AA potentially reflects decreased AA in 
phospholipid membranes, limiting the availability of AA for oxidation by COX II and 
ensuing PGE2 production. Therefore, by altering plasma AA concentrations, CLA 
supplementation in horses may help prevent inflammation and reduce a pro-inflammatory 
state. 
 Although CLA was present in plasma and available for use by body tissues, 
dietary CLA treatment failed to demonstrate effects on synovial PGE2 and serum DPD 
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and BAP.  Despite a reduction in circulating AA in CLA treated mares, PGE2 
concentrations in SF were not different between treatments. There was no treatment 
effect on kinematic parameters of mares. Supplementation of CLA did not cause changes 
in BW, BCS or RFT in mares, suggesting that CLA supplementation at the current 
inclusion rate and duration of supplementation does not alter fat storage or mobilization 
to the degree of causing measureable changes in body fat.   
 The data represented in this research project provide a valuable basis for the 
continued study of CLA supplementation in horses. We have shown that CLA 
supplementation increases plasma CLA isomer concentrations and decreases plasma AA 
concentrations. Therefore, CLA supplementation may offer a more effective alternative 
than fish oil supplementation for reducing inflammation, although further research is 
necessary to elucidate its effects. Additional research utilizing an exercised, OA, or other 
in vivo or in vitro research model with a pro-inflammatory stressor would help define the 
possible anti-inflammatory effects of CLA and its role in reducing or preventing 
inflammation associated with OA.  
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Appendix A 
ANOVA Tables 
 
Appendix A.1.  ANOVA Table body weight (kg) 
Source DF Type III SS Mean 
Square 
F value Pr > F 
Horse(seq) 10 605.96 60.60 1.63 0.2267 
Treatment 1 13.50 13.5 0.36 0.5602 
Period 1 36.51 36.51 0.98 0.3451 
Error 10 371.78 37.18   
Sequence 1 45.93 45.93 0.76 0.4044 
Error 10 605.96 60.60   
 
Appendix A.2.  ANOVA Table body condition score 
Source DF Type III SS Mean 
Square 
F value Pr > F 
Horse(seq) 10 3.92 0.39 1.38 0.3091 
Treatment 1 0.04 0.04 0.15 0.7094 
Period 1 0.38 0.38 1.32 0.2767 
Error 10 2.83 0.28   
Sequence 1 0.67 0.67 1.70 0.2212 
Error 10 3.92 0.39   
 
Appendix A.3.  ANOVA Table rump fat thickness (cm) 
Source DF Type III SS Mean 
Square 
F value Pr > F 
Horse(seq) 10 0.30 0.03 2.73 0.0643 
Treatment 1 0.04 0.04 3.94 0.0753 
Period 1 0 0 0 1.00 
Error 10 0.11 0.01   
Sequence 1 0.01 0.01 0.23 0.6414 
Error 10 0.29 0.03   
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Appendix A.4.  ANOVA Table serum deoxypyridinoline (nmol/L) 
Source DF Type III SS Mean 
Square 
F value Pr > F 
Horse(seq) 10 18.50 1.85 0.80 0.6382 
Treatment 1 0.25 0.25 0.11 0.7517 
Period 1 0.60 0.60 0.26 0.6254 
Error 8 18.55 2.32   
Sequence 1 0.77 0.77 0.41 0.5342 
Error 11.96 22.53 1.88   
 
Appendix A.5.  ANOVA Table serum bone alkaline phosphatase (U/L) 
Source DF Type III SS Mean 
Square 
F value Pr > F 
Horse(seq) 10 1032.20 103.22 1.30 0.3450 
Treatment 1 0.10 0.10 0.00 0.9725 
Period 1 6.50 6.50 0.08 0.7810 
Error 10 796.68 79.67   
Sequence 1 19.45 19.45 0.19 0.6734 
Error 10 1032.20 103.22   
 
Appendix A.6.  ANOVA Table synovial prostaglandin E2 (pg/mL) 
Source DF Type III SS Mean 
Square 
F value Pr > F 
Horse(seq) 10 39514 3951.39 14.62 0.0002 
Treatment 1 610.01 610.01 2.26 0.1673 
Period 1 6458.19 6458.19 23.89 0.0009 
Error 10 2432.95 270.33   
Sequence 1 101.55 101.55 0.03 0.8733 
Error 10.06 38162 3792.88   
 
Appendix A.7.  ANOVA Type 3 fixed effects of plasma cis-9, trans-11 CLA 
Effect Num DF Denom DF F Value Pr > F 
Sequence 1 10 3.58 0.0877 
Period 1 76 3.58 0.0622 
Treatment 1 76 222.21 < 0.0001 
Day 3 76 43.13 < 0.0001 
Trt*Day 
interaction 
3 76 43.13 < 0.0001 
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Appendix A.8.  ANOVA Type 3 fixed effects of plasma trans-10, cis-12 CLA 
Effect Num DF Denom DF F Value Pr > F 
Sequence 1 10 6.38 0.0301 
Period 1 76 6.38 0.0136 
Treatment 1 76 215.26 < 0.0001 
Day 3 76 97.74 < 0.0001 
Trt*Day 
interaction 
3 76 97.74 < 0.0001 
 
Appendix A.9.  ANOVA Type 3 fixed effects of plasma trans-9, trans-11 CLA 
Effect Num DF Denom DF F Value Pr > F 
Sequence 1 10 14.19 0.0037 
Period 1 76 14.19 0.0003 
Treatment 1 76 430.49 < 0.0001 
Day 3 76 26.36 < 0.0001 
Trt*Day 
interaction 
3 76 26.36 < 0.0001 
 
Appendix A.10.  ANOVA Type 3 fixed dffects of plasma arachidonic acid 
Effect Num DF Denom DF F Value Pr > F 
Sequence 1 10 1.08 0.3238 
Period 1 76 49.87 < 0.0001 
Treatment 1 76 28.83 < 0.0001 
Day 3 76 28.99 < 0.0001 
Trt*Day 
interaction 
3 76 5.00 0.0032 
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Appendix B 
Raw Data Tables 
Appendix B.1.  Raw data table CLA isomer and AA plasma concentration (percent of 
total plasma fatty acids) 
   Obs   HORSE  TREATMENT   PERIOD   day    c9t11    t10c12  t9t11   c204AA   seq 
     1    Ariel        CO          1       0      0.000     0.000    0.000    1.43500    AB 
     2    Dixie        CO          1       0      0.000     0.000    0.000    1.25900    AB 
     3    Dove         CLA         1       0      0.000     0.000    0.875    1.13000    BA 
     4    Kismet       CLA         1       0      0.000     0.000    0.000    1.16700    BA 
     5    Leda         CLA         1       0      0.000     0.000    0.780    1.32400    BA 
     6    May          CO          1       0      0.000     0.000    0.000    1.17400    AB 
     7    Sara         CO          1       0      0.000     0.000    0.000    1.11600    AB 
     8    Sierra       CO          1       0      0.000     0.000    0.000    1.10500    AB 
     9    Sonny        CLA         1       0      0.000     0.000    0.000    1.10000    BA 
    10    Tooni        CLA         1       0      0.000     0.000    0.000    1.17500    BA 
    11    Z            CO          1       0      0.000     0.000    0.000    1.31900    AB 
    12    Zephyr       CLA         1       0      0.000     0.000    0.000    1.60800    BA 
    13    Ariel        CO          1       14     0.000     0.000    0.000    1.50300    AB 
    14    Dixie        CO          1       14     0.000     0.000    0.000    1.23500    AB 
    15    Dove         CLA         1       14     0.857     0.809    1.425    0.94900    BA 
    16    Kismet       CLA         1       14     0.926     0.823    1.425    0.95700    BA 
    17    Leda         CLA         1       14     0.883     0.803    1.270    0.97300    BA 
    18    May          CO          1       14     0.000     0.000    0.000    1.03700    AB 
    19    Sara         CO          1       14     0.000     0.000    0.000    0.93600    AB 
    20    Sierra       CO          1       14     0.000     0.000    0.000    0.87200    AB 
    21    Sonny        CLA         1       14     1.067     0.921    1.377    0.62100    BA 
    22    Tooni        CLA         1       14     1.006     0.943    1.401    0.82700    BA 
    23    Z            CO          1       14     0.000     0.000    0.000    1.05800    AB 
    24    Zephyr       CLA         1       14     1.091     1.032    1.032    1.05200    BA 
    25    Ariel        CO          1       28     0.000     0.000    0.000    1.32502    AB 
    26    Dixie        CO          1       28     0.000     0.000    0.000    1.16345    AB 
    27    Dove         CLA         1       28     0.797     0.782    1.352    0.75842    BA 
    28    Kismet       CLA         1       28     0.904     0.864    1.086    0.93466    BA 
    29    Leda         CLA         1       28     0.904     0.768    0.985    0.78639    BA 
    30    May          CO          1       28     0.000     0.000    0.000    0.93377    AB 
    31    Sara         CO          1       28     0.000     0.000    0.000    0.81533    AB 
    32    Sierra       CO          1       28     0.000     0.000    0.000    0.81781    AB 
    33    Sonny        CLA         1       28     0.691     0.616    1.012    0.64796    BA 
    34    Tooni        CLA         1       28     1.091     1.033    1.553    0.70886    BA 
    35    Z            CO          1       28     0.000     0.000    0.000    1.06725    AB 
    36    Zephyr       CLA         1       28     0.969     0.887    1.440    0.90037    BA 
    37    Ariel        CO          1       42     0.000     0.000    0.000    1.18300    AB 
    38    Dixie        CO          1       42     0.000     0.000    0.000    1.09900    AB 
    39    Dove         CLA         1       42     0.813     0.763    1.274    0.67700    BA 
    40    Kismet       CLA         1       42     0.907     0.803    1.114    0.78700    BA 
    41    Leda         CLA         1       42     0.946     0.821    1.385    0.78600    BA 
    42    May          CO          1       42     0.000     0.000    0.000    1.02800    AB 
    43    Sara         CO          1       42     0.000     0.000    0.000    0.91100    AB 
    44    Sierra       CO          1       42     0.000     0.000    0.000    0.81500    AB 
    45    Sonny        CLA         1       42     1.045     0.906    1.546    0.54200    BA 
    46    Tooni        CLA         1       42     1.523     1.516    1.816    0.62100    BA 
    47    Z            CO          1       42     0.000     0.000    0.000    1.02100    AB 
    48    Zephyr       CLA         1       42     1.124     1.026    1.089    0.85400    BA 
    49    Ariel        CLA         2       0      0.689     0.471    0.818    1.17800    AB 
    50    Dixie        CLA         2       0      0.000     0.000    0.708    1.16100    AB 
    51    Dove         CO          2       0      0.000     0.000    0.000     0.924     BA 
    52    Kismet       CO          2       0      0.000     0.000    0.000     1.096     BA 
    53    Leda         CO          2       0      0.000     0.000    0.000     0.996     BA 
    54    May          CLA         2       0      0.000     0.531    0.911     1.096     AB 
    55    Sara         CLA         2       0      0.672     0.491    1.261     0.906     AB 
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     56    Sierra       CLA         2       0      0.689     0.523    0.882     0.936    AB 
     57    Sonny        CO          2       0      0.000     0.000    0.000     0.753    BA 
     58    Tooni        CO          2       0      0.000     0.000    0.000     0.973    BA 
     59    Z            CLA         2       0      0.000     0.000    0.711     1.057    AB 
     60    Zephyr       CO          2       0      0.000     0.000    0.000     1.097    BA 
     61    Ariel        CLA         2       14     0.519     0.501    1.663     1.180    AB 
     62    Dixie        CLA         2       14     0.687     0.640    1.101     1.129    AB 
     63    Dove         CO          2       14     0.000     0.000    0.000     0.784    BA 
     64    Kismet       CO          2       14     0.000     0.000    0.000     0.994    BA 
     65    Leda         CO          2       14     0.000     0.000    0.000     0.927    BA 
     66    May          CLA         2       14     0.715     0.699    1.819     0.818    AB 
     67    Sara         CLA         2       14     0.866     0.851    2.150     0.789    AB 
     68    Sierra       CLA         2       14     0.954     0.867    2.005     0.706    AB 
     69    Sonny        CO          2       14     0.000     0.000    0.000     0.659    BA 
     70    Tooni        CO          2       14     0.000     0.000    0.000     0.731    BA 
     71    Z            CLA         2       14     0.534     0.578    1.257     0.867    AB 
     72    Zephyr       CO          2       14     0.000     0.000    0.000     0.971    BA 
     73    Ariel        CLA         2       28     0.991     1.150    1.599     1.099    AB 
     74    Dixie        CLA         2       28     0.807     0.753    1.304     0.999    AB 
     75    Dove         CO          2       28     0.000     0.000    0.000     0.784    BA 
     76    Kismet       CO          2       28     0.000     0.000    0.000     1.033    BA 
     77    Leda         CO          2       28     0.000     0.000    0.000     0.942    BA 
     78    May          CLA         2       28     1.136     1.100    1.795     0.663    AB 
     79    Sara         CLA         2       28     1.220     1.161    2.206     0.657    AB 
     80    Sierra       CLA         2       28     1.094     0.946    1.524     0.679    AB 
     81    Sonny        CO          2       28     0.000     0.000    0.000     0.677    BA 
     82    Tooni        CO          2       28     0.000     0.000    0.000     0.680    BA 
     83    Z            CLA         2       28     0.736     0.751    1.473     0.777    AB 
     84    Zephyr       CO          2       28     0.000     0.000    0.000     0.973    BA 
     85    Ariel        CLA         2       42     0.659     0.667    1.513     1.199    AB 
     86    Dixie        CLA         2       42     0.810     0.761    1.340     0.959    AB 
     87    Dove         CO          2       42     0.000     0.000    0.000     0.843    BA 
     88    Kismet       CO          2       42     0.000     0.000    0.000     1.098    BA 
     89    Leda         CO          2       42     0.000     0.000    0.000     0.989    BA 
     90    May          CLA         2       42     0.824     0.785    1.803     0.644    AB 
     91    Sara         CLA         2       42     0.999     0.929    1.740     0.702    AB 
     92    Sierra       CLA         2       42     1.262     1.108    1.946     0.649    AB 
     93    Sonny        CO          2       42     0.000     0.000    0.000     0.688    BA 
     94    Tooni        CO          2       42     0.000     0.000    0.000     0.768    BA 
     95    Z            CLA         2       42     0.785     0.771    1.571     0.729    AB 
     96    Zephyr       CO          2       42     0.000     0.000    0.000     1.012    BA 
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Appendix B.2.  Raw data table body weight (kg) 
Horse Treatment Period Day 0 Day 42 Diff(D 42 - D 0) 
Ariel CO 1 1081 1079 -2 
Dixie CO 1 1263 1247 -16 
Dove CLA 1 1257 1272 15 
Kismet CLA 1 1080 1079 -1 
Leda CLA 1 1365 1354 -11 
May CO 1 1235 1246 11 
Sara CO 1 1161 1164 3 
Sierra CO 1 1185 1186 1 
Sunny CLA 1 1225 1225 0 
Tooni CLA 1 1294 1310 16 
Z CO 1 1245 1254 9 
Zephyr CLA 1 1338 1342 4 
Ariel CLA 2 1075 1063 -12 
Dixie CLA 2 1253 1240 -13 
Dove CO 2 1258 1235 -23 
Kismet CO 2 1071 1058 -13 
Leda CO 2 1329 1336 7 
May CLA 2 1232 1229 -3 
Sara CLA 2 1165 1167 2 
Sierra CLA 2 1196 1181 -15 
Sunny CO 2 1239 1226 -13 
Tooni CO 2 1276 1327 51 
Z CLA 2 1260 1255 -5 
Zephyr CO 2 1330 1331 1 
 
Appendix B.3.  Raw data table body condition score 
Horse Treatment Period Day 0 Day 46 Diff (D 42 - D 0) 
Ariel CO 1 5 4.5 -0.5 
Dixie CO 1 4.5 4 -0.5 
Dove CLA 1 6 7 1 
Kismet CLA 1 4 4.5 0.5 
Leda CLA 1 5 4.5 -0.5 
May CO 1 5.5 6 0.5 
Sara CO 1 5.5 5.5 0 
Sierra CO 1 6.5 6.5 0 
Sonny CLA 1 7 6.5 -0.5 
Tooni CLA 1 5 6 1 
Z CO 1 5.5 6.5 1 
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Zephyr CLA 1 7 7.5 0.5 
Ariel CLA 2 5 4.5 -0.5 
Dixie CLA 2 4.5 4.5 0 
Dove CO 2 7 6.5 -0.5 
Kismet CO 2 4.5 4.5 0 
Leda CO 2 4.5 4.5 0 
May CLA 2 7 6 -1 
Sara CLA 2 6 5.5 -0.5 
Sierra CLA 2 6.5 6.5 0 
Sonny CO 2 7 7 0 
Tooni CO 2 6 6.5 0.5 
Z CLA 2 6 6.5 0.5 
Zephyr CO 2 7 8 1 
 
Appendix B.4.  Raw data table rump fat thickness (cm) 
Horse Treatment Period Day 0 Day 42 Diff (D 42 - D 0) 
Ariel CO 1 0.7 0.4 -0.3 
Dixie CO 1 0.3 0.2 -0.1 
Dove CLA 1 1.3 1.2 -0.1 
Kismet CLA 1 1.1 1.15 0.05 
Leda CLA 1 1.15 1.2 0.05 
May CO 1 0.75 0.9 0.15 
Sara CO 1 1.1 1.15 0.05 
Sierra CO 1 0.9 1 0.1 
Sonny CLA 1 1 0.9 -0.1 
Tooni CLA 1 1.6 1.8 0.2 
Z CO 1 1.6 1.65 0.05 
Zephyr CLA 1 2.3 2.45 0.15 
Ariel CLA 2 0.45 0.35 -0.1 
Dixie CLA 2 0.1 0.3 0.2 
Dove CO 2 1.35 1.3 -0.05 
Kismet CO 2 1.15 1.1 -0.05 
Leda CO 2 1.3 1.15 -0.15 
May CLA 2 0.95 1.15 0.2 
Sara CLA 2 1 1 0 
Sierra CLA 2 1 0.9 -0.1 
Sonny CO 2 1.1 0.95 -0.15 
Tooni CO 2 2.2 2.25 0.05 
Z CLA 2 1.8 2.05 0.25 
Zephyr CO 2 2.55 2.65 0.1 
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Appendix B.5.  Raw data table serum deoxypyridinoline (nmol/L) concentration 
Horse Treatment Period Day 0  Day 42 Diff (D 42 - D 0) 
Ariel CO 1 6.8985 7.0034 0.1049 
Dixie CO 1 3.717 4.267 0.55 
Dove CLA 1 5.3205 5.4533 0.1328 
Kismet CLA 1 . 7.3696 . 
Leda CLA 1 3.8857 5.0507 1.165 
May CO 1 . 6.229 . 
Sara CO 1 3.5452 5.2762 1.731 
Sierra CO 1 5.6889 5.5869 -0.102 
Sonny CLA 1 4.1909 3.956 -0.2349 
Tooni CLA 1 5.9324 3.8946 -2.0378 
Z CO 1 4.3127 6.0907 1.778 
Zephyr CLA 1 3.3644 5.8902 2.5258 
Ariel CLA 2 6.7089 7.4534 0.7445 
Dixie CLA 2 5.3235 4.1818 -1.1417 
Dove CO 2 4.347 7.0828 2.7358 
Kismet CO 2 6.6494 5.7563 -0.8931 
Leda CO 2 6.4148 4.7597 -1.6551 
May CLA 2 4.9278 4.7735 -0.1543 
Sara CLA 2 5.6032 5.3484 -0.2548 
Sierra CLA 2 5.4243 6.1464 0.7221 
Sonny CO 2 5.994 3.6734 -2.3206 
Tooni CO 2 4.2124 5.2543 1.0419 
Z CLA 2 4.1997 5.3482 1.1485 
Zephyr CO 2 4.4661 5.6016 1.1355 
 
Appendix B.6.  Raw data table serum bone alkaline phosphatase (U/L) concentration 
Horse Treatment Period Day 0 Day 42 Diff (D 42 - D 0) 
Ariel CO 1 67.053 82.686 15.633 
Dixie CO 1 38.757 26.264 -12.493 
Dove CLA 1 40.907 20.058 -20.85 
Kismet CLA 1 34.729 33.398 -1.331 
Leda CLA 1 26.563 18.283 -8.28 
May CO 1 35.828 20.94 -14.889 
Sara CO 1 39.917 28.189 -11.728 
Sierra CO 1 29.746 16.46 -13.286 
Sonny CLA 1 33.773 20.905 -12.868 
Tooni CLA 1 39.426 20.632 -18.794 
Z CO 1 37.528 17.248 -20.28 
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Zephyr CLA 1 35.73 29.234 -6.496 
Ariel CLA 2 59.476 53.521 -5.955 
Dixie CLA 2 28.732 14.341 -14.391 
Dove CO 2 27.302 17.347 -9.955 
Kismet CO 2 34.047 20.427 -13.62 
Leda CO 2 16.509 17.15 0.64 
May CLA 2 27.45 29.336 1.886 
Sara CLA 2 41.25 17.199 -24.051 
Sierra CLA 2 21.881 15.277 -6.604 
Sonny CO 2 36.299 11.926 -24.374 
Tooni CO 2 22.032 11.088 -10.944 
Z CLA 2 29.78 14.833 -14.947 
Zephyr CO 2 38.654 22.817 -15.838 
 
Appendix B.7.  Raw data table synovial prostaglandin E2 (pg/mL) concentrations 
Horse Treatment Period Day 0 Day 42 Diff (D 42 - D 0) 
Ariel CO 1 60.8213 76.8954 16.0741 
Dixie CO 1 41.9852 51.6094 9.6242 
Dove CLA 1 50.2899 94.0476 43.7577 
Kismet CLA 1 48.7525 50.1324 1.3799 
Leda CLA 1 65.2448 70.9723 5.7275 
May CO 1 130.4733 105.0674 -25.4059 
Sara CO 1 59.6698 64.1129 4.4431 
Sierra CO 1 72.4027 66.8962 -5.5065 
Sonny CLA 1 216.8255 88.5694 -128.2561 
Tooni CLA 1 37.9443 63.0035 25.0592 
Z CO 1 40.8833 49.7705 8.8872 
Zephyr CLA 1 46.9928 69.8783 22.8855 
Ariel CLA 2 114.9556 50.8472 -64.1084 
Dixie CLA 2 48.6148 49.7423 1.1275 
Dove CO 2 99.4026 81.4291 -17.9735 
Kismet CO 2 62.4728 38.31 -24.1628 
Leda CO 2 44.2356 50.1263 5.8907 
May CLA 2 119.2687 50.3544 -68.9143 
Sara CLA 2 77.1697 31.4565 -45.7132 
Sierra CLA 2 98.7071 46.7929 -51.9142 
Sonny CO 2 201.5774 49.7669 -151.8105 
Tooni CO 2       . 47.1412                 . 
Z CLA 2 67.8509 35.5826 -32.2683 
Zephyr CO 2 65.8711 80.2511 14.38 
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Appendix B.8.  Raw data table stride length (cm), speed (cm/sec) and duration (sec) at 
the walk 
Horse Treatment Day 
Stride 
Length 
(cm) 
Speed 
(cm/sec) 
Duration 
(sec) 
Ariel CO 0 149.46 109.98 1.358974 
Dixie CO 0 159.94 140.41 1.139093 
Dove CLA 0 150.63 134.03 1.123853 
Kismet CLA 0 160.89 130.23 1.23543 
Leda CLA 0 156.81 126.55 1.239115 
May CO 0 154.14 132.60 1.162487 
Sara CO 0 152.96 115.74 1.321583 
Sierra CO 0 137.17 115.43 1.188339 
Sonny CLA 0 151.13 134.00 1.127836 
Tooni CLA 0 153.33 125.24 1.224289 
Z CO 0 133.89 112.95 1.185392 
Zephyr CLA 0 140.95 98.56 1.430093 
Ariel CO 42 169.13 128.99 1.311187 
Dixie CO 42 160.25 125.82 1.273645 
Dove CLA 42 154.99 138.48 1.119223 
Kismet CLA 42 160.38 132.58 1.209685 
Leda CLA 42 156.55 134.52 1.163767 
May CO 42 158.25 136.56 1.158831 
Sara CO 42 151.64 132.23 1.14679 
Sierra CO 42 139.67 120.89 1.155348 
Sonny CLA 42 156 138.28 1.128146 
Tooni CLA 42 156.22 127.10 1.229111 
Z CO 42 151.96 141.27 1.075671 
Zephyr CLA 42 156 119.81 1.302062 
 
 
Appendix B.9.  Raw data table stride length (cm), speed (cm/sec) and duration (sec) at 
the trot 
Horse Treatment Day 
Stride 
Length (cm) 
Speed 
(cm/sec) 
Duration 
(sec) 
Ariel CO 0 164.26 219.76 0.75 
Dixie CO 0 200.35 279.57 0.72 
Dove CLA 0 . . . 
Kismet CLA 0 192.88 279.40 0.69 
Leda CLA 0 209.50 287.95 0.73 
May CO 0 195.38 322.25 0.61 
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Sara CO 0 167.31 241.41 0.69 
Sierra CO 0 191.36 278.60 0.69 
Sonny CLA 0 197.38 299.98 0.66 
Tooni CLA 0 186.07 253.24 0.73 
Z CO 0 179.67 258.07 0.70 
Zephyr CLA 0 170.21 227.44 0.75 
Ariel CO 42 204.75 267.26 0.77 
Dixie CO 42 199.38 259.60 0.77 
Dove CLA 42 . . . 
Kismet CLA 42 177.38 245.34 0.72 
Leda CLA 42 199.49 255.50 0.78 
May CO 42 169.86 259.66 0.65 
Sara CO 42 179.51 263.32 0.68 
Sierra CO 42 158.67 225.11 0.70 
Sonny CLA 42 181.29 274.33 0.66 
Tooni CLA 42 182.16 249.14 0.73 
Z CO 42 170.15 247.30 0.69 
Zephyr CLA 42 172.67 237.35 0.73 
 
 
Appendix B.10.  Raw data table palmar fetlock extension and flexion angle (°) at the 
walk and trot 
Horse Treatment Day 
Walk 
Extension 
Walk 
Flexion 
Trot 
Extension 
Trot 
Flexion 
Ariel CO 0 223.5 153.5 235.75 153.5 
Dixie CO 0 221.4 . 229.15 . 
Dove CLA 0 221.6 . . . 
Kismet CLA 0 228.85 . 241.7 . 
Leda CLA 0 227.8 139.87 237.8 . 
May CO 0 233 . 242.05 . 
Sara CO 0 221.4 150.67 234.15 . 
Sierra CO 0 228.95 . 244.4 . 
Sonny CLA 0 235.6 154.4 246.55 132.19 
Tooni CLA 0 231.7 166.31 242.85 145.6 
Z CO 0 229.5 . 235.7 . 
Zephyr CLA 0 220.5 150.15 233.55 127.6 
Ariel CO 42 225.4 153 246.8 145.5 
Dixie CO 42 224.05 . 233.7 . 
Dove CLA 42 228.2 . 241.2 . 
Kismet CLA 42 . . 244.15 . 
Leda CLA 42 232.85 153.4 242.7 . 
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May CO 42 235.65 . 246.85 . 
Sara CO 42 229.65 168.9 241.65 . 
Sierra CO 42 229.8 . 242.35 . 
Sonny CLA 42 232 154.38 241.15 146.45 
Tooni CLA 42 231.4 165.35 246.95 155.45 
Z CO 42 231.6 . 241.8 . 
Zephyr CLA 42 224.4 160.7 237.1 137.47 
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